"Rank","NCT Number","Title","Status","Study Results","Conditions","Interventions","First Posted","Locations","URL"
1,"NCT04360330","SABER Study for Selected Early Stage Breast Cancer","Recruiting","No Results Available","Breast Cancer|Early-stage Breast Cancer","Radiation: Stereotactic Ablative Breast Radiotherapy","April 24, 2020","University of Miami, Miami, Florida, United States","https://ClinicalTrials.gov/show/NCT04360330"
2,"NCT04217109","Transcutaneous Breast Cancer Diagnosis by Canine Odorology","Recruiting","No Results Available","Breast Cancer","Diagnostic Test: Odour sampling","January 3, 2020","Institut de Cancérologie de l'Ouest, Nantes, France|Centre d'imagerie 114, Paris, France|Groupe Hospitalier Paris Saint- Joseph, Paris, France|Institut Curie, Paris, France|Institut Curie, Saint-Cloud, France|Centre Hospitalier Valenciennes, Valenciennes, France","https://ClinicalTrials.gov/show/NCT04217109"
3,"NCT04413409","A Trial Evaluating the Efficacy of Metastasectomy in Patients With Oligo-Metastatic Breast Cancer(OMIT)","Recruiting","No Results Available","Breast Cancer","Procedure: Metastasectomy for the metastatic sites","June 4, 2020","Fudan University Shanghai Cancer Center, Shanghai, China","https://ClinicalTrials.gov/show/NCT04413409"
4,"NCT04240548","Radiation Therapy for ypN0 Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Radiation: Regional Nodal Irradiation","January 27, 2020","National Cancer Institute, Cairo, Egypt","https://ClinicalTrials.gov/show/NCT04240548"
5,"NCT04387630","Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.","Recruiting","No Results Available","Breast Cancer","Drug: Metformin|Drug: Placebo oral tablet","May 14, 2020","Mansoura University Cancer center, Mansoura, Egypt","https://ClinicalTrials.gov/show/NCT04387630"
6,"NCT04265274","Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.","Recruiting","No Results Available","Metastatic Breast Cancer","Drug: Disulfiram|Drug: Vinorelbin|Drug: Cisplatin|Drug: Copper","February 11, 2020","National Cancer Institute, Bratislava, Slovakia","https://ClinicalTrials.gov/show/NCT04265274"
7,"NCT04289532","Integrin α6-targeted SPECT Imaging of Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: 99mTc-RWY","February 28, 2020","Peking University Health Science Center, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04289532"
8,"NCT04379908","Healthy Lifestyles and Quality of Life in Women With Breast Cancer","Completed","No Results Available","Breast Cancer",,"May 8, 2020","Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain|Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Galicia, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|Centro Oncológico de Galicia, A Coruña, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitario Virgen de los Lirios, Alicante, Spain|Hospital Clinic i Provincial, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Puerta del Mar, Cadiz, Spain|ICO de Girona, Hospital Dr. Josep Trueta, Gerona, Spain|Complejo Hospitalario de Jaén, Jaen, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitario Virgen de la Salud, Toledo, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT04379908"
9,"NCT04228432","E-monitoring of Patients Under Adjuvant Hormonotherapy for Breast Cancer.","Recruiting","No Results Available","Breast Cancer","Other: Dedicated and coordinated monitoring","January 14, 2020","Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France","https://ClinicalTrials.gov/show/NCT04228432"
10,"NCT04350229","Endocrinological Changes Due to Pre-medications of Chemotherapy in Patients With Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Drug omission|Other: Control group","April 16, 2020","Vanessa Scontre, São Paulo, SP, Brazil","https://ClinicalTrials.gov/show/NCT04350229"
11,"NCT04431674","Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients With Chest-wall and Locally-Advanced Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Definity Suspension for Injection","June 16, 2020","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04431674"
12,"NCT04302415","Metabolomics Explores Biomarkers for Metastatic Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: There is no other intervention, only clinical treatment.","March 10, 2020","Shandong Cancer Hospital and Institute, Jinan, Shandong, China","https://ClinicalTrials.gov/show/NCT04302415"
13,"NCT04270149","Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Biological: ESR1 peptide vaccine","February 17, 2020",,"https://ClinicalTrials.gov/show/NCT04270149"
14,"NCT04250818","Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile","Recruiting","No Results Available","Metastatic Triple-Negative Breast Cancer",,"January 31, 2020","Texas Tech University HSC El Paso, El Paso, Texas, United States","https://ClinicalTrials.gov/show/NCT04250818"
15,"NCT04215003","A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC","Not yet recruiting","No Results Available","Breast Cancer","Drug: A|Drug: B|Drug: CL1|Drug: CL2|Drug: CLH1|Drug: CLH2|Drug: CH1|Drug: CH2|Drug: CT1","January 2, 2020",,"https://ClinicalTrials.gov/show/NCT04215003"
16,"NCT04365790","Investigation of Gene Mutations in Patients With Triple-negative and Patients With HER2+ Breast Cancer Adenocarcinoma","Recruiting","No Results Available","Breast Cancer",,"April 28, 2020","George Fountzilas, Athens, Greece","https://ClinicalTrials.gov/show/NCT04365790"
17,"NCT04277338","Molecular Imaging of HER2 Expression in Breast Cancer Using Technetium-99m-labelled DARPin HE3-G3 (99mTc-HE3-G3)","Enrolling by invitation","No Results Available","Primary Breast Cancer","Diagnostic Test: SPECT","February 20, 2020","TomskNRMC, Tomsk, Russian Federation","https://ClinicalTrials.gov/show/NCT04277338"
18,"NCT04223492","Liquid Biopsies and Imaging in Breast Cancer","Recruiting","No Results Available","Breast Cancer","Diagnostic Test: Liquid biopsy|Diagnostic Test: Multi-parametric MRI","January 10, 2020","Universitair Medisch Centrum Utrecht, Utrecht, Netherlands","https://ClinicalTrials.gov/show/NCT04223492"
19,"NCT04289935","Vacuum Assisted Biopsy Immediately Before Surgery as an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Procedure: Vacuum assisted biopsy (VAB)","February 28, 2020","Kantonsspital Baden, Baden, Switzerland|Universitätsspital Basel, Basel, Switzerland|Bethesda Spital, Basel, Switzerland|IOSI - Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland|Inselspital - Universitätsklinik für Frauenklinik, Bern, Switzerland|Hirslanden Brustzentrum Bern Biel, Bern, Switzerland|Kantonsspital Graubünden, Chur, Switzerland|Brustzentrum Thurgau, Frauenfeld, Switzerland|Clinique de Genolier, Genolier, Switzerland|Luzerner Kantonsspital, Luzern, Switzerland|Hirslanden Klinik St. Anna, Luzern, Switzerland|Gesundheitszentrum Fricktal, Rheinfelden, Switzerland|Tumor- und Brustzentrum ZeTuP St. Gallen, St. Gallen, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland|Brustzentrum Ostschweiz, St. Gallen, Switzerland|Brust-Zentrum Seefeld, Zürich, Switzerland","https://ClinicalTrials.gov/show/NCT04289935"
20,"NCT04320979","Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer","Radiation: internal mammary nodal irradiation|Radiation: no internal mammary nodal irradiation","March 25, 2020","Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China","https://ClinicalTrials.gov/show/NCT04320979"
21,"NCT04411966","Early Interim 18F-FDG-PET and 18F-FLT-PET for Predicting Treatment Response and Survival in Metastatic Breast Cancer","Completed","No Results Available","Metastatic Breast Cancer","Diagnostic Test: 18F-fluorothymidine","June 2, 2020",,"https://ClinicalTrials.gov/show/NCT04411966"
22,"NCT04429269","A Comparative Study of Mammography and Ultrasound for Breast Cancer Screening and Early Diagnosis","Recruiting","No Results Available","Breast Cancer Diagnosis|Breast Cancer Screening","Diagnostic Test: mammography and ultrasound screening","June 12, 2020","Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04429269"
23,"NCT04419181","Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer","Not yet recruiting","No Results Available","HER2-positive Breast Cancer","Drug: Docetaxel|Drug: Carboplatin|Drug: Trastuzumab|Drug: Pertuzumab|Drug: Trastuzumab emtansine","June 5, 2020",,"https://ClinicalTrials.gov/show/NCT04419181"
24,"NCT04315012","Training With Mobile Application in Breast Cancer","Completed","No Results Available","Breast Cancer","Other: receive mobile app-based education","March 19, 2020","İzmir Bakırçay University, İzmir, Turkey","https://ClinicalTrials.gov/show/NCT04315012"
25,"NCT04292821","BIOPSY SCANNER LLTECH© Technology for Diagnosis of Breast Cancer","Recruiting","No Results Available","Breast Cancer",,"March 3, 2020","Hôpital de la Pitié Salpêtrière, Paris, France","https://ClinicalTrials.gov/show/NCT04292821"
26,"NCT04220476","CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer","Recruiting","No Results Available","Breast Cancer","Radiation: Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|Drug: Letrozole 2.5Mg Tab|Drug: Palbociclib 125mg","January 7, 2020","Weill Cornell Medicine, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04220476"
27,"NCT04261244","NeoRad Breast Cancer Study","Not yet recruiting","No Results Available","Breast Cancer","Radiation: preoperative radiotherapy|Radiation: postoperative radiotherapy","February 7, 2020","Heinrich Heine University Hospital Duesseldorf, Duesseldorf, Germany","https://ClinicalTrials.gov/show/NCT04261244"
28,"NCT04374825","Optimizing Quality of Life in Women Living With Metastatic Breast Cancer","Active, not recruiting","No Results Available","Metastatic Breast Cancer","Behavioral: Acceptance and Commitment Therapy (ACT)|Behavioral: Cognitive Behavioral Stress Management (CBSM)","May 5, 2020","Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT04374825"
29,"NCT04307407","Exercise in Breast Cancer Survivors","Enrolling by invitation","No Results Available","Breast Cancer","Behavioral: Aerobic Exercise","March 13, 2020","Norwegian School of Sport Sciences, Oslo, Norway","https://ClinicalTrials.gov/show/NCT04307407"
30,"NCT04353557","ctDNA Monitoring in Early Breast Cancer","Recruiting","No Results Available","Breast Cancer",,"April 20, 2020","Army Medical Center of PLA, China, Chongqing, Chongqing, China","https://ClinicalTrials.gov/show/NCT04353557"
31,"NCT04437160","Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy","Recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Epirubicin or Pirarubicin|Drug: Cyclophosphamide","June 18, 2020","Cancer Hospital & Institute Chinese Academy of Medical Sciences (CAMS), Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04437160"
32,"NCT04312347","Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels","Recruiting","No Results Available","ER+ Breast Cancer","Drug: Tamoxifen dose adjustment","March 18, 2020","MRCCC Siloam Hospital Semanggi, Jakarta, DKI Jakarta, Indonesia","https://ClinicalTrials.gov/show/NCT04312347"
33,"NCT04328194","Autotaxin (ATX) as a Marker for Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Diagnostic Test: Serum Autotaxin|Radiation: chest x-ray|Diagnostic Test: Breast ultrasound or mammography|Diagnostic Test: Histopathological examination of breast mass specimens|Radiation: Magnetic Resonance Imaging ( MRI) and Bone scan|Diagnostic Test: Peripheral haemogram|Diagnostic Test: Renal and liver functions|Diagnostic Test: Prothrombin time and concentration|Diagnostic Test: Cancer Antigen 15-3 (CA15-3).|Other: Full medical history|Other: Full clinical examination","March 31, 2020",,"https://ClinicalTrials.gov/show/NCT04328194"
34,"NCT04430595","Multi-4SCAR-T Therapy Targeting Breast Cancer","Recruiting","No Results Available","Breast Cancer","Biological: 4SCAR T cells","June 12, 2020","The Seventh Affilliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, China","https://ClinicalTrials.gov/show/NCT04430595"
35,"NCT04296175","Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)","Recruiting","No Results Available","Triple-negative Breast Cancer","Drug: Epirubicin|Drug: CTX|Drug: Paclitaxel|Drug: ddEpirubicin|Drug: ddCTX|Drug: Paclitaxel(with carbo)|Drug: Carboplatin","March 5, 2020","Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04296175"
36,"NCT04298333","Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer","Completed","No Results Available","Metastatic Breast Cancer|Stage IV Breast Cancer","Drug: BP-C1","March 6, 2020","Sanglah University Hospital, Bali, Indonesia|National Taiwan University Hospital, Taipei, Taiwan|Siriraj Hospital, Mahidol University, Bangkok, Thailand","https://ClinicalTrials.gov/show/NCT04298333"
37,"NCT04258163","Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy","Completed","No Results Available","Metastatic Breast Cancer","Drug: Capecitabine|Drug: Liposomal doxorubicin|Drug: Gemcitabine|Drug: Fulvestrant|Drug: Anastrozole|Drug: Letrozole","February 6, 2020","First People's Hospital of Foshan, Foshan, Guangdong, China|Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT04258163"
38,"NCT04305496","Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2− Breast Cancer","Recruiting","No Results Available","Locally Advanced (Inoperable) or Metastatic Breast Cancer","Drug: Fulvestrant|Drug: Capivasertib|Drug: Placebo","March 12, 2020","Research Site, Gilbert, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Orange, California, United States|Research Site, Redlands, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Maria, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Whittier, California, United States|Research Site, Fort Myers, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Marietta, Georgia, United States|Research Site, Westwood, Kansas, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Royal Oak, Michigan, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Henderson, Nevada, United States|Research Site, Paramus, New Jersey, United States|Research Site, Farmington, New Mexico, United States|Research Site, Lake Success, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Midlothian, Virginia, United States|Research Site, Puyallup, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Berazategui, Argentina|Research Site, Ciudad Autonoma De Buenos Aire, Argentina|Research Site, La Rioja, Argentina|Research Site, Rosario, Argentina|Research Site, Viedma, Argentina|Research Site, Adelaide, Australia|Research Site, Ballarat, Australia|Research Site, Birtinya, Australia|Research Site, Box Hill, Australia|Research Site, Concord, Australia|Research Site, East Albury, Australia|Research Site, Kurralta Park, Australia|Research Site, North Sydney, Australia|Research Site, Orange, Australia|Research Site, Ringwood East, Australia|Research Site, South Brisbane, Australia|Research Site, Waratah, Australia|Research Site, Wendouree, Australia|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Charleroi, Belgium|Research Site, Edegem, Belgium|Research Site, Namur, Belgium|Research Site, Wilrijk, Belgium|Research Site, Winnipeg, Manitoba, Canada|Research Site, Kingston, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Besancon, France|Research Site, Brest, France|Research Site, Metz Cedex 03, France|Research Site, Montpellier, France|Research Site, Pierre Benite CEDEX, France|Research Site, Plerin SUR MER, France|Research Site, Pringy, France|Research Site, Rouen, France|Research Site, STRASBOURG Cedex, France|Research Site, Toulouse cedex 9, France|Research Site, Berlin, Germany|Research Site, Cottbus, Germany|Research Site, Dresden, Germany|Research Site, Erlangen, Germany|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Frankfurt, Germany|Research Site, Gelsenkirchen, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Jena, Germany|Research Site, Kiel, Germany|Research Site, Magdeburg, Germany|Research Site, Mannheim, Germany|Research Site, Minden, Germany|Research Site, Muenchen, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Münster, Germany|Research Site, Paderborn, Germany|Research Site, Potsdam, Germany|Research Site, Sömmerda, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Kecskemét, Hungary|Research Site, Pécs, Hungary|Research Site, Szekszárd, Hungary|Research Site, Szolnok, Hungary|Research Site, Afula, Israel|Research Site, Be'er Sheva, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar-Saba, Israel|Research Site, Petah Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Bergamo, Italy|Research Site, Candiolo, Italy|Research Site, Catanzaro, Italy|Research Site, Genova, Italy|Research Site, Livorno, Italy|Research Site, Macerata, Italy|Research Site, Meldola, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Modena, Italy|Research Site, Napoli, Italy|Research Site, Prato, Italy|Research Site, Reggio Nell'emilia, Italy|Research Site, Roma, Italy|Research Site, Chiba-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukushima-shi, Japan|Research Site, Hidaka-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kitaadachi-gun, Japan|Research Site, Koto-ku, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Ota-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Sunto-gun, Japan|Research Site, Tsu-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Daegu, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seo-Gu, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Arequipa, Peru|Research Site, Lima, Peru|Research Site, Bydgoszcz, Poland|Research Site, Krakow, Poland|Research Site, Olsztyn, Poland|Research Site, Warszawa, Poland|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, A Coruña, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Córdoba, Spain|Research Site, Hosp de Llobregat(Barcelona), Spain|Research Site, Jaén, Spain|Research Site, La Laguna (Tenerife), Spain|Research Site, Lérida, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Malaga, Spain|Research Site, Pamplona, Spain|Research Site, Reus,Tarragona, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Kaohsiung City, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Aberdeen, United Kingdom|Research Site, Bangor, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Cheltenham, United Kingdom|Research Site, Derby, United Kingdom|Research Site, Huddersfield, United Kingdom|Research Site, Lancaster, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Sutton, United Kingdom|Research Site, York, United Kingdom","https://ClinicalTrials.gov/show/NCT04305496"
39,"NCT04267900","99mTc-HPArk2 SPECT/CT for the Detection of HER2-positive Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: 99mTc-HPArk2","February 13, 2020","Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04267900"
40,"NCT04225741","Theory-based Training to Promote Breast Cancer Screening","Completed","No Results Available","Breast Cancer|Breast Cancer Female","Behavioral: Training group","January 13, 2020",,"https://ClinicalTrials.gov/show/NCT04225741"
41,"NCT04274946","Sentinel Lymph Node Biopsy With Hybrid Technique in Breast Cancer","Recruiting","No Results Available","Breast Cancer","Procedure: Sentinel lymph node biopsy","February 18, 2020","Bülent Ecevit University, Zonguldak, Turkey","https://ClinicalTrials.gov/show/NCT04274946"
42,"NCT04272801","Neoadjuvant Endocrine Therapy Tolerance in Geriatric Early Stage ER+ Breast Cancer","Recruiting","No Results Available","Breast Cancer Female","Drug: tamoxifen, letrozole, anastrozole, or exemestane|Behavioral: Patient reported outcomes","February 17, 2020","University of Virginia, Charlottesville, Virginia, United States","https://ClinicalTrials.gov/show/NCT04272801"
43,"NCT04307329","Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial","Not yet recruiting","No Results Available","Breast Cancer","Biological: Monalizumab|Biological: Trastuzumab","March 13, 2020","NKI-AVL, Amsterdam, Netherlands","https://ClinicalTrials.gov/show/NCT04307329"
44,"NCT04307147","NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy","Recruiting","No Results Available","Breast Cancer","Drug: Capecitabine|Drug: Vinorelbine","March 13, 2020","Cancer Hospital/ Institute, Fudan University, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04307147"
45,"NCT04427215","Complementary and Alternative Medicine on Mental Health in Breast Cancer Patients","Not yet recruiting","No Results Available","Breast Cancer","Other: Complementary and alternative medicines","June 11, 2020","Cesar Agostinis-Sobrinho, Klaipeda, Lithuania","https://ClinicalTrials.gov/show/NCT04427215"
46,"NCT04234386","GammaPod Dose Escalation Radiation for Early Stage Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Radiation: GammaPod Radiation","January 21, 2020",,"https://ClinicalTrials.gov/show/NCT04234386"
47,"NCT04434677","Hypofractionation And Ultra-Hypofractionation In Adjuvant Radiotherapy For Breast Cancer","Recruiting","No Results Available","Breast Cancer","Radiation: Hypofractionation|Radiation: ultraHypofractionation","June 17, 2020","ACOD, Alexandria, Egypt","https://ClinicalTrials.gov/show/NCT04434677"
48,"NCT04215146","A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study","Recruiting","No Results Available","Breast Cancer Metastatic","Drug: Paclitaxel|Biological: Pelareorep|Drug: Avelumab","January 2, 2020","Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States|West Virginia University, Morgantown, West Virginia, United States","https://ClinicalTrials.gov/show/NCT04215146"
49,"NCT04339517","Postoperative Identification of Tumor Cells at the Lumpectomy Site of Patients With Early Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Procedure: Aspiration of seroma fluid","April 9, 2020",,"https://ClinicalTrials.gov/show/NCT04339517"
50,"NCT04303988","A Multi-cohort Phase II Study of HER2-positive and Triple-negative Breast Cancer Brain Metastases.","Not yet recruiting","No Results Available","Breast Cancer","Drug: Pyrotinib|Drug: Temozolomide Injection|Drug: SHR-1316|Drug: Bevacizumab|Drug: Cisplatin/Carboplatin","March 11, 2020",,"https://ClinicalTrials.gov/show/NCT04303988"
51,"NCT04383275","Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)","Not yet recruiting","No Results Available","Breast Cancer","Drug: capecitabine and trastuzumab|Drug: endocrine therapy and trastuzumab","May 12, 2020",,"https://ClinicalTrials.gov/show/NCT04383275"
52,"NCT04334785","Evaluation for the Effectiveness and Safety of Cryo-ablation in the Treatment of Early Invasive Breast Cancer","Recruiting","No Results Available","Breast Cancer","Device: cryo-ablation","April 6, 2020","Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04334785"
53,"NCT04255056","Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab","Not yet recruiting","No Results Available","Breast Cancer","Drug: Pyrotinib","February 5, 2020","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT04255056"
54,"NCT04394325","Digi-Do - a Digital Information Tool to Help Patients Diagnosed With Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Behavioral: Digital information tool","May 19, 2020",,"https://ClinicalTrials.gov/show/NCT04394325"
55,"NCT04289974","Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Palbociclib","February 28, 2020","Cancer Hospital, ChineseAMS, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04289974"
56,"NCT04362826","Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Biological: Novel probiotic|Other: Placebo","April 27, 2020","Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT04362826"
57,"NCT04360616","The Diagnosis and Prognosis of Nonpalpable Breast Cancer Detected by the US vs Mammography: a Clinical Noninferiority Trial.","Recruiting","No Results Available","Breast Cancer","Diagnostic Test: imaging","April 24, 2020","The First Affiliated Hospital of Fourth Military Medical University, Xi'an, Shaanxi, China","https://ClinicalTrials.gov/show/NCT04360616"
58,"NCT04219267","Effectiveness of Character Strengths-based Intervention Among Breast Cancer Patients","Not yet recruiting","No Results Available","Breast Cancer","Behavioral: character strengths-based intervention|Behavioral: early memories","January 7, 2020",,"https://ClinicalTrials.gov/show/NCT04219267"
59,"NCT04280536","Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA)","Recruiting","No Results Available","Breast Cancer","Drug: Cohort A|Drug: Cohort B","February 21, 2020","National University Hospital, Singapore, Singapore","https://ClinicalTrials.gov/show/NCT04280536"
60,"NCT04247633","High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)","Recruiting","No Results Available","Breast Cancer","Drug: Palbociclib","January 30, 2020","Samsung Medical Center, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT04247633"
61,"NCT04261153","Use of Cognitive Stimulation Software for Patients Over the Age of 70 Followed for Breast Cancer: COG-TAB-AGE Feasibility Study","Recruiting","No Results Available","Breast Cancer","Other: Cognitive stimulation","February 7, 2020","Centre François Baclesse, Caen, France|Centre Henri Becquerel, Rouen, France","https://ClinicalTrials.gov/show/NCT04261153"
62,"NCT04397185","Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer Female","Device: Breast Cancer Locator (BCL) guided partial mastectomy|Device: Wire Localized (WL) partial mastectomy","May 21, 2020",,"https://ClinicalTrials.gov/show/NCT04397185"
63,"NCT04366713","A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib","Recruiting","No Results Available","HER2 Amplified Breast Cancer","Drug: Neratinib|Drug: Capecitabine|Drug: Loperamide","April 29, 2020","Hospital CUF Descobertas, Lisboa, Portugal","https://ClinicalTrials.gov/show/NCT04366713"
64,"NCT04396626","HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes","Active, not recruiting","No Results Available","Breast Cancer",,"May 20, 2020","Pfizer United States, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04396626"
65,"NCT04308720","Circulating Tumor DNA and Immunophenotyping as Potential Biomarkers in Patients Undergoing Regional Nodal Irradiation for Breast Cancer","Recruiting","No Results Available","Breast Cancer",,"March 16, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT04308720"
66,"NCT04281355","Individualized Locoregional Treatment of Initially Biopsy-proven Node-positive Breast Cancer After Primary Systemic Therapy","Not yet recruiting","No Results Available","Breast Cancer","Procedure: Omission of axillary lymph node dissection|Radiation: Omission of regional irradiation","February 24, 2020",,"https://ClinicalTrials.gov/show/NCT04281355"
67,"NCT04400695","A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2","Not yet recruiting","No Results Available","Breast Cancer","Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets","May 22, 2020",,"https://ClinicalTrials.gov/show/NCT04400695"
68,"NCT04316156","Real-time Interactive Digital Healthcare System in Patients With Breast Cancer; Randomized Controlled Trial","Recruiting","No Results Available","Breast Cancer","Device: Uincare Homeplus|Other: Brochure","March 20, 2020","Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of|Department of rehabilitation, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Seocho-gu, Korea, Republic of","https://ClinicalTrials.gov/show/NCT04316156"
69,"NCT04248998","Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer","Recruiting","No Results Available","Triple-negative Breast Cancer","Dietary Supplement: Fasting-mimicking diet|Drug: Metformin|Drug: Preoperative chemotherapy","January 30, 2020","Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy","https://ClinicalTrials.gov/show/NCT04248998"
70,"NCT04248257","Peer Support For Young Adult Women With High Breast Cancer Risk","Not yet recruiting","No Results Available","Breast Cancer Risk","Behavioral: PeACE|Behavioral: Community peer coaching","January 30, 2020","Georgetown University, Washington, District of Columbia, United States","https://ClinicalTrials.gov/show/NCT04248257"
71,"NCT04270032","Using Deep Learning Methods to Analyze Automated Breast Ultrasound Images, to Establish a Diagnosis, Therapy Assessment and Prognosis Prediction Model of Breast Cancer.","Recruiting","No Results Available","Breast Cancer","Diagnostic Test: ABUS","February 17, 2020","The First Affiliated Hospital of Fourth Military Medical University, Xi'an, Shaanxi, China","https://ClinicalTrials.gov/show/NCT04270032"
72,"NCT04354675","Effectiveness of AI Genetic Counseling Program vs In-person Genetic Counseling in Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Genetic: Automated program (ChatBot)|Genetic: Genetics counselor|Other: BCGCKQ Survey|Other: Satisfaction Survey|Genetic: Genetic testing","April 21, 2020","Cleveland Clinic, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT04354675"
73,"NCT04385433","A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Drug: EXPERIMENTAL ARM|Other: CONTROL GROUP","May 13, 2020","Icm Val D'Aurelle, Montpellier, Herault, France","https://ClinicalTrials.gov/show/NCT04385433"
74,"NCT04290793","Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Drug: Pyrotinib|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Taxanes|Biological: Trastuzumab","March 2, 2020",,"https://ClinicalTrials.gov/show/NCT04290793"
75,"NCT04224922","Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Paclitaxel|Drug: Carboplatinum|Drug: Epirubicin|Drug: Cyclophosphamide","January 13, 2020","Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium|Cliniques Sud Luxembourg, Arlon, Belgium|Imelda Ziekenhuis, Bonheiden, Belgium|AZ klina, Brasschaat, Belgium|St Lucas, Brugge, Belgium|Institut Jules Bordet, Brussels, Belgium|Universitaire Ziekenhuis Antwerpen, Edegem, Belgium|AZ Maria Middelares, Gent, Belgium|AZ St Lucas, Gent, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|CHR Citadelle, Liège, Belgium|CHU Sart-Tilman, Liège, Belgium|CMSE, Namur, Belgium|Clinique st Pierre, Ottignies, Belgium|CHWAPI, Tournai, Belgium|CHR Verviers, Verviers, Belgium|CHU Mont-Godinne, Yvoir, Belgium","https://ClinicalTrials.gov/show/NCT04224922"
76,"NCT04261218","Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Drug: tomivosertib|Drug: paclitaxel","February 7, 2020","Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Vancouver, Vancouver, British Columbia, Canada|Jewish General Hospital, Montreal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT04261218"
77,"NCT04292847","LCCC1931:Post-treatment Intervention in Women With Breast Cancer (70y/o+)","Suspended","No Results Available","Breast Cancer","Other: Referrals Recommendations","March 3, 2020","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States","https://ClinicalTrials.gov/show/NCT04292847"
78,"NCT04258735","Genetic Characteristics of Metastatic Breast Cancer Patients","Recruiting","No Results Available","Metastatic Breast Cancer","Diagnostic Test: Genomic analysis","February 6, 2020","Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT04258735"
79,"NCT04240106","Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-negative,ER-positive) and gBRCA or HDR-positive Metastatic Breast Cancer(LUZERN)","Not yet recruiting","No Results Available","Breast Cancer|Breast Cancer Metastatic","Drug: Niraparib 100 MG|Drug: Aromatase Inhibitors","January 27, 2020","Centro Oncologico de Galicia, A Coruña, Spain|Hospital Uniersitario Vall d'Hebron, Barcelona, Spain|Hospital Clínic i provincial de Barcelona, Barcelona, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de octubre, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Hospital Clínico Universitario de Santiago de Compostela, Santiago De Compostela, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Complejo Asistencial de Ávila, Ávila, Spain","https://ClinicalTrials.gov/show/NCT04240106"
80,"NCT04394247","Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy","Not yet recruiting","No Results Available","Breast Cancer",,"May 19, 2020",,"https://ClinicalTrials.gov/show/NCT04394247"
81,"NCT04296162","Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)","Recruiting","No Results Available","Breast Cancer","Drug: Vinorelbine|Drug: Capecitabine|Drug: Trastuzumab","March 5, 2020","Zhi-Ming Shao, Shanghai, China","https://ClinicalTrials.gov/show/NCT04296162"
82,"NCT04259866","FALSE POSITIVE FINDINGS IN BREAST CANCER TOMOSYNTHESIS","Completed","No Results Available","Breast Cancer Screening",,"February 7, 2020","Graziella Di Grezia, Avellino, Av, Italy","https://ClinicalTrials.gov/show/NCT04259866"
83,"NCT04301739","to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)","Not yet recruiting","No Results Available","Triple Negative Breast Cancer","Drug: HLX10|Drug: nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide|Drug: Placebo","March 10, 2020",,"https://ClinicalTrials.gov/show/NCT04301739"
84,"NCT04440982","Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients Receiving Neoadjuvant Therapy","Not yet recruiting","No Results Available","Breast Cancer|Neoadjuvant Therapy","Combination Product: Study Device Arm","June 22, 2020","Stanford University Medical Center, Palo Alto, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04440982"
85,"NCT04382352","B002 in Patients With HER2-positive Breast Cancer","Recruiting","No Results Available","Recurrent Breast Cancer|Metastatic Breast Cancer","Biological: Humanized Anti-HER2 Monoclonal Antibody Compound for Injection .R&D code: B002.","May 11, 2020","Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04382352"
86,"NCT04269967","A Pilot Tele-rehabilitation Trial for Breast Cancer Survivors","Not yet recruiting","No Results Available","Breast Cancer Female","Other: Receiving routine rehabilitation care via tele-rehabilitation system","February 17, 2020","Miho Asano, Singapore, Singapore","https://ClinicalTrials.gov/show/NCT04269967"
87,"NCT04298918","A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Drug: Placebo|Drug: Venetoclax|Drug: Trastuzumab emtansine","March 6, 2020","Yale Cancer Center, New Haven, Connecticut, United States|Dana Farber Cancer Inst., Boston, Massachusetts, United States|Washington University; Division of Oncology, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|SCRI-Tennessee Oncology, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Peter MacCallum Cancer Center, Melbourne, Victoria, Australia|IOV - Istituto Oncologico Veneto IRCCS, Padova, Veneto, Italy|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Hospital Universitari Vall d'Hebron; Oncology, Barcelona, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT04298918"
88,"NCT04335006","A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.","Not yet recruiting","No Results Available","Breast Cancer|Triple Negative Breast Cancer","Drug: Carelizumab|Drug: Nab-paclitaxel|Drug: Apatinib","April 6, 2020",,"https://ClinicalTrials.gov/show/NCT04335006"
89,"NCT04337736","Effects of Physical Exercise on Cardio-vascular Efficiency and Quality of Life in Breast Cancer Survivors","Completed","No Results Available","Breast Cancer Female","Other: Physical exercise","April 8, 2020",,"https://ClinicalTrials.gov/show/NCT04337736"
90,"NCT04436393","Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer","Not yet recruiting","No Results Available","Advanced Breast Cancer","Diagnostic Test: Guardant360 test","June 18, 2020",,"https://ClinicalTrials.gov/show/NCT04436393"
91,"NCT04373031","Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer|Breast Neoplasms","Drug: Pembrolizumab|Drug: IRX 2","May 4, 2020",,"https://ClinicalTrials.gov/show/NCT04373031"
92,"NCT04370522","Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer","Not yet recruiting","No Results Available","Metastatic Breast Cancer",,"May 1, 2020","Hospital General Universitario Morales Meseguer, Murcia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT04370522"
93,"NCT04344496","East Asian Breast Cancer Genome Atlas and Recurrence Risk Prediction","Recruiting","No Results Available","Breast Cancer","Other: PAM50","April 14, 2020","National Taiwan University Hospital, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT04344496"
94,"NCT04398914","Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer Invasive","Drug: Pyrotinib|Drug: Trastuzumab|Drug: Pertuzumab|Drug: Nab-paclitaxel|Drug: EC chemotherapy|Drug: Physician's choice|Drug: T-DM1|Procedure: Surgery","May 22, 2020",,"https://ClinicalTrials.gov/show/NCT04398914"
95,"NCT04407988","Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer","Recruiting","No Results Available","Metastatic Breast Cancer","Drug: Pyrotinib Maleate plus Letrozole","May 29, 2020","Hunan Cancer Hospital, Changsha, Hunan, China","https://ClinicalTrials.gov/show/NCT04407988"
96,"NCT04389073","Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine","Recruiting","No Results Available","Metastatic Breast Cancer","Drug: Vinorelbine 40mg|Drug: Toripalimab 240mg","May 15, 2020","Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China|Beijing Huanxing Cancer Hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04389073"
97,"NCT04304352","Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients","Recruiting","No Results Available","Advanced Breast Cancer","Drug: Vinorelbine|Drug: Capecitabine|Drug: Cyclophosphamide","March 11, 2020","European Institute of Oncology, Milan, Italy","https://ClinicalTrials.gov/show/NCT04304352"
98,"NCT04293276","Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer","Not yet recruiting","No Results Available","Metastatic Breast Cancer","Drug: Pyrotinib|Drug: SHR6390","March 3, 2020","Henan Cancer Hospital, Zhengzhou, Henan, China","https://ClinicalTrials.gov/show/NCT04293276"
99,"NCT04253561","Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients","Recruiting","No Results Available","Metastatic Breast Cancer","Drug: Ipatasertib|Drug: Trastuzumab|Drug: Pertuzumab","February 5, 2020","ICO Badalona, Badalona, Barcelona, Spain|Comp. Hosp.Univ. Santiago (Chus), Santiago De Compostela, La Coruña, Spain|Hospital Universitario del Vall d' Hebron, Barcelona, Spain|H.Univ. Arnau de Vilanova de Lleida, Lleida, Spain|Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain|Hospital Universitario Doce de Octubre, Madrid, Spain|MD Anderson, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Virgen de Macarena, Sevilla, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain","https://ClinicalTrials.gov/show/NCT04253561"
100,"NCT04247035","Τreatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer","Recruiting","No Results Available","Metastatic Breast Cancer",,"January 29, 2020","Hellenic Society of Medical Oncology, Athens, Greece","https://ClinicalTrials.gov/show/NCT04247035"
101,"NCT04293393","Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients","Not yet recruiting","No Results Available","Early Breast Cancer","Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Taxane|Drug: Letrozole|Drug: Abemaciclib|Drug: LHRH Analogue","March 3, 2020","Complejo Hospitalario Universitario de Santiago (CHUS), Santiago De Compostela, A Coruña, Spain|Institut Català d'Oncología (ICO) L'Hospitalet, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain|Consorcio Hospitalario Provincial de Castellón, Castellón De La Plana, Castelló, Spain|Hospital Universitario Donostia, San Sebastián, Donostia, Spain|Hospital Álvaro Cunqueiro, Vigo, Pontevedra, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitario de Badajoz, Badajoz, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Universitario San Pedro de Alcántara, Cáceres, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Institut Català d'Oncología (ICO) Girona, Girona, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz De Tenerife, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Virgen de la Salud, Toledo, Spain|Fundación Instituto Valenciano de Oncología (FIVO), Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Universitari i Politécnic La Fe, Valencia, Spain|Hospital Universitario Reina Sofía, Valencia, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT04293393"
102,"NCT04367090","Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer","Not yet recruiting","No Results Available","Metastatic Breast Cancer","Drug: Docetaxel, trastuzumab|Drug: Pyrotinib|Drug: Pyrotinib, docetaxel and trastuzumab","April 29, 2020",,"https://ClinicalTrials.gov/show/NCT04367090"
103,"NCT04432454","Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation","Not yet recruiting","No Results Available","Metastatic Breast Cancer","Drug: Lasofoxifene and abemaciclib (VERZENIO (R).","June 16, 2020",,"https://ClinicalTrials.gov/show/NCT04432454"
104,"NCT04243616","Study of PD-1 Inhibition With Cemiplimab in Locally Advanced Hormone Receptor (HR) Positive HER2 Negative or Triple-Negative Breast Cancer Patients Undergoing Standard Neoadjuvant Chemotherapy","Suspended","No Results Available","Invasive Breast Cancer","Drug: Cemiplimab|Drug: Paclitaxel|Drug: Carboplatin (not mandatory)|Drug: Doxorubicin|Drug: Cyclophosphamide","January 28, 2020","Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT04243616"
105,"NCT04343079","Intra-operative PET-CT: a Novel Approach to Determine Excision Margins in Lumpectomy Breast Cancer.","Recruiting","No Results Available","Breast Cancer Female|Breast Neoplasms","Diagnostic Test: PET CT","April 13, 2020","University Hospital Ghent, Ghent, Oost Vlaanderen, Belgium","https://ClinicalTrials.gov/show/NCT04343079"
106,"NCT04246502","Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer","Not yet recruiting","No Results Available","Metastatic Breast Cancer","Drug: Capecitabine and Pyrotinib|Drug: Capecitabine,Trastuzumab, and Pertuzumab","January 29, 2020",,"https://ClinicalTrials.gov/show/NCT04246502"
107,"NCT04364672","Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Drug: [11C]PiB and 18F-labeled DPA-714 PET scan","April 28, 2020","The University of Alabama at Birmingham, Birmingham, Alabama, United States","https://ClinicalTrials.gov/show/NCT04364672"
108,"NCT04432727","Study Evaluating Flexitouch Plus With Connectivity on Compliance in 30 Patients With Breast Cancer-Related Lymphedema.","Not yet recruiting","No Results Available","Breast Cancer Lymphedema","Device: Flexitouch Plus with Cellular Connectivity (FT-CC)","June 16, 2020",,"https://ClinicalTrials.gov/show/NCT04432727"
109,"NCT04354233","A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer","Not yet recruiting","No Results Available","Metastatic Breast Cancer","Device: Physical activity intervention with connected devices","April 21, 2020","CHU Amiens - Site Nord, Amiens, France|CHU Amiens - Site Sud, Amiens, France|Institut de Cancérologie de l'Ouest (ICO), Angers, France|CHU Avignon, Avignon, France|CHRU Besançon, Besançon, France|CH Fleyriat, Bourg-en-Bresse, France|Centre Léon Bérard (CLB), Lyon, France|Clinique Charcot, Lyon, France|CH Morlaix, Morlaix, France|Institut Godinot, Reims, France|Institut de Cancérologie Lucien Neuwirth (ICLN), Saint-Étienne, France","https://ClinicalTrials.gov/show/NCT04354233"
110,"NCT04436744","A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of GDC-9545 Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer","Not yet recruiting","No Results Available","Early Breast Cancer","Drug: GDC-9545|Drug: Anastrozole|Drug: Palbociclib|Procedure: Surgery","June 18, 2020",,"https://ClinicalTrials.gov/show/NCT04436744"
111,"NCT04263298","Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Combination Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer","Recruiting","No Results Available","Metastatic Breast Cancer","Drug: Fulvestrant|Drug: Capecitabine Oral Product","February 10, 2020","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Public Health Institute of Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|Fifth Subsidiary Sun Yat-sen University Hospital, Zhuhai, Guangdong, China","https://ClinicalTrials.gov/show/NCT04263298"
112,"NCT04268693","Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer","Not yet recruiting","No Results Available","Triple Negative Breast Cancer","Other: urine collection","February 13, 2020","Milken Institute School of Public Health, George Washington University, Washington, District of Columbia, United States","https://ClinicalTrials.gov/show/NCT04268693"
113,"NCT04318223","Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy","Recruiting","No Results Available","Metastatic Breast Cancer|Locally Advanced Breast Cancer","Drug: Palbociclib","March 23, 2020","Nuovo ospedale di Prato - S. Stefano, Prato, Firenze, Italy|Ospedale Civile S. Giovanni di Dio, Frattamaggiore, Napoli, Italy|Centro di Riferimento oncologico, Aviano, Pordenone, Italy|Fondazione del Piemonte per l'Oncologia, Candiolo, Torino, Italy|Ospedale Sacro Cuore di Gesù Fatebenefratelli, Benevento, Italy|A.O. Osp. Riuniti - ASST PAPA GIOVANNI 23, Bergamo, Italy|Ospedale di Brindisi ""Perrino"", Brindisi, Italy|Ospedale Policnico San Martino, Genova, Italy|Ospedale Vito Fazzi, Lecce, Italy|Azienda Ospedaliera Papardo, Messina, Italy|Azienda Ospedaliero - Universitaria di Modena, Modena, Italy|A.O.U. Seconda Universita' degli Studi di Napoli, Napoli, Italy|Azienda Ospedaliera 'A. CARDARELLI', Napoli, Italy|Azienda Ospedaliera dei Colli - P.Monaldi, Napoli, Italy|Istituto Nazionale Tumori IRCCS Pascale, Napoli, Italy|Università degli Studi di Napoli ""Federico II"", Napoli, Italy|A.O.U. Pisana, Pisa, Italy|Istituto Nazionale Tumori Regina Elena (IRE, Roma, Italy|Ospedale Sandro Pertini, Roma, Italy","https://ClinicalTrials.gov/show/NCT04318223"
114,"NCT04251169","Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression","Not yet recruiting","No Results Available","Metastatic Breast Cancer","Drug: Pembrolizumab|Drug: Paclitaxel","January 31, 2020","ICO Hospitalet, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebrón, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario 12 de octubre, Madrid, Spain|Hospital Quiron Salud Sagrado Corazon Sevilla, Sevilla, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT04251169"
115,"NCT04362462","Molecular Profiling After Neoadjuvant Chemotherapy for Triple-negative Breast Cancer","Recruiting","No Results Available","Triple-negative Breast Cancer",,"April 27, 2020","Texas Tech University Health Sciences Center- El Paso, El Paso, Texas, United States","https://ClinicalTrials.gov/show/NCT04362462"
116,"NCT04254263","Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer","Not yet recruiting","No Results Available","Locally Advanced Breast Cancer","Drug: pyrotinib","February 5, 2020","Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04254263"
117,"NCT04227327","Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)","Recruiting","No Results Available","Advanced Breast Cancer","Drug: Abemaciclib|Drug: Aromatase Inhibitors","January 13, 2020","AOU ospedali riuniti Ancona clinica oncologica, Ancona, Italy|ASL di Asti D.H. - oncologia, Asti, Italy|IRCCS Istituto Oncologico Giovanni Paolo II, Bari, Italy|ULSS 1 Belluno Ospedale San Martino, Belluno, Italy|Humanitas Gavazzeni, Bergamo, Italy|ASST degli Spedali civili, Brescia, Italy|Ospedale ""SS Annuziata"" clinica oncologica, Chieti, Italy|ASST Lariana, Como, Italy|ASST Cremona Istituti ospitalieri Cremona, Cremona, Italy|ASST Monza, Ospedale di Desio, Desio, Italy|AUSL Romagna ospedale per gli infermi - patologia mammaria, Faenza, Italy|Azienda ospedaliera S. Antonio abate, Gallarate, Italy|AUSL di Reggio Emilia clinica oncologica Guastalla, Guastalla, Italy|Ospedale San Salvatore di L'Aquila, L'Aquila, Italy|Azienda ospedaliera cardinale Giovanni Panico, Lecce, Italy|AUSL Toscana Nord Ovest Livorno, Livorno, Italy|ASST Fatebenefratelli Sacco Ospedale Sacco, Milano, Italy|ASST Monza, Ospedale San Gerardo, Monza, Italy|ASL 2 Olbia, Olbia, Italy|Ospedale La Maddalena, Palermo, Italy|Policlinico universitario di Palermo - oncologia medica, Palermo, Italy|AUSL di Piacenza Ospedale ""Guglielmo da Saliceto"", Piacenza, Italy|Arcispedale S. Maria nuova, Reggio Emilia, Italy|ASST Rhodense ospedale di circolo Rho, Rho, Italy|AUSL Romagna ospedale di Rimini, Rimini, Italy|Istituto Nazionale dei tumori Regina Elena- oncologia medica A, Roma, Italy|Istituto Nazionale dei tumori Regina Elena- oncologia medica B, Roma, Italy|Humanitas research hospital, Rozzano, Italy|ASST Valle Olona P.O. SARONNO, Saronno, Italy|A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy|AOU Città della salute e della scienza - Breast Unit, Torino, Italy|ASL Torino presidio ospedaliero Martini, Torino, Italy|Clinica ostetrico-ginecologica S. Anna, Torino, Italy|APSS provincia autonoma di Trento Ospedale di Trento, Trento, Italy|ASST Settelaghi Varese, Varese, Italy|ULSS 8 Berica Ospedale San Bortolo, Vicenza, Italy","https://ClinicalTrials.gov/show/NCT04227327"
118,"NCT04222426","89Zr-atezolizumab PET Scan and Lobular Breast Cancer","Recruiting","No Results Available","Lobular Metastatic Breast Cancer","Other: 89Zr-atezolizumab PET scans","January 10, 2020","University Medical Center Groningen, Groningen, Netherlands","https://ClinicalTrials.gov/show/NCT04222426"
119,"NCT04403529","Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer","Recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Traditional Chinese Medicine Formulation|Drug: Placebo Formulation","May 27, 2020","Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04403529"
120,"NCT04320030","[18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers","Not yet recruiting","No Results Available","Triple Negative Breast Cancer","Drug: [18F]-DPA-714 PET/CT scan","March 24, 2020","Institut de Cacerologie de l'ouest - site Paul Papin, Angers, France|APHP - Hôpital Tenon, Paris, France|Institut de cancerologie de l'Ouest, Saint Herblain, France|CHU Bretonneau, Tours, France","https://ClinicalTrials.gov/show/NCT04320030"
121,"NCT04418154","Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients","Recruiting","No Results Available","Triple Negative Breast Cancer","Drug: epirubicin hydrochloride|Drug: Cyclophosphamide|Drug: Albumin bound paclitaxel|Drug: Toripalimab","June 5, 2020","Shanghai Cancer Center, Fudan University, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04418154"
122,"NCT04332588","Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI","Not yet recruiting","No Results Available","HER2-positive Breast Cancer","Drug: [18F]FMISO PET/MRI imaging","April 2, 2020","The University of Alabama at Birmingham, Birmingham, Alabama, United States","https://ClinicalTrials.gov/show/NCT04332588"
123,"NCT04438681","Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients","Not yet recruiting","No Results Available","Triple Negative Breast Cancer",,"June 19, 2020","Centre Jean PERRIN, Clermont-Ferrand, France","https://ClinicalTrials.gov/show/NCT04438681"
124,"NCT04331067","Cabiralizumab in Combination With Nivolumab and Neoadjuvant Chemotherapy in Patients With Localized Triple-negative Breast Cancer","Not yet recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Paclitaxel|Drug: Carboplatin|Biological: Nivolumab|Biological: Cabiralizumab|Procedure: Tumor biopsy|Procedure: Bone marrow|Procedure: Blood draw","April 2, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States","https://ClinicalTrials.gov/show/NCT04331067"
125,"NCT04297657","Using BETTER Model Sexual Problems in Breast Cancer","Completed","No Results Available","Sexuality|Breast Cancer","Other: Counselling","March 5, 2020",,"https://ClinicalTrials.gov/show/NCT04297657"
126,"NCT04298086","A Study of the Body's Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women With Breast Cancer","Recruiting","No Results Available","Breast Cancer|Primary Hormone Receptor Positive Breast Cancer","Other: Exercise Treatment|Other: Plant-Based Diet|Other: Physical activity|Other: Nutrition counseling","March 6, 2020","Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States|Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States","https://ClinicalTrials.gov/show/NCT04298086"
127,"NCT04378751","Promoting Genetic Counseling Among African American Women With a Family History of Breast Cancer","Not yet recruiting","No Results Available","High Risk for Breast Cancer","Behavioral: Decision aid video|Other: Genetic counseling informational brochure","May 7, 2020","UIC Cancer Center, Chicago, Illinois, United States|University of Illinois at Chicago Hospital and Ambulatory Clinics, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT04378751"
128,"NCT04405505","A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)","Not yet recruiting","No Results Available","Triple Negative Breast Cancer","Drug: TQB2450|Drug: Anlotinib|Drug: Paclitaxel for Injection (albumin bound)","May 28, 2020","The Fourth Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|Chinese Academy of Medical Sciencesand Peking Union Medical College Hospital, Beijing, Beijing, China|Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing, Beijing, China|Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China|Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China|Chongqing Cancer Hospital, Chongqing, Chongqing, China|The First Affilited Hospital of Chongqing Medical University, Chongqing, Chongqing, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi Zhuang Autonomous Region, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China|The fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Affiliated Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang, China|AnYang Tumor Hospital, Anyang, Henan, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Hunan Cancer Hospital, Changsha, Hunan, China|Nantong Tumor Hospital, Nantong, Jiangsu, China|The First Hospital of Jilin University, Changchun, Jilin, China|Yanbian University Hospital, Yanji, Jilin, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Shanxi Cancer Hospital, Taiyuan, Shanxi, China|The Second Affiliated Hospital of PLA Airforce Military Medical University, Xi'an, Shanxi, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China|Shanxi Provincial People's Hospital, Xi'an, Shanxi, China|The Second People's Hospital of Neijiang, Neijiang, Sichuan, China|Tianjin Cancer Hospital, Tianjin, Tianjin, China|Xinjiang Uiger Municipal People's Hospital, Urumqi, Xinjiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China","https://ClinicalTrials.gov/show/NCT04405505"
129,"NCT04427293","Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)","Not yet recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Lenvatinib|Drug: Pembrolizumab","June 11, 2020",,"https://ClinicalTrials.gov/show/NCT04427293"
130,"NCT04232319","Feasibility and Effectiveness of a Sleep Hygiene Education Program for Sleep Issues in Breast Cancer Survivors","Recruiting","No Results Available","Breast Cancer|Sleep Hygiene","Behavioral: Sleep Hygiene Training","January 18, 2020","University of Toledo, Toledo, Ohio, United States","https://ClinicalTrials.gov/show/NCT04232319"
131,"NCT04328610","To Assess the Efficacy of the LYMPHA in the Prevention of Lymphedema Following Axillary Dissection for Breast Cancer","Not yet recruiting","No Results Available","Lymphedema, Breast Cancer","Procedure: LYMPHA(LYmphatic Microsurgical Preventive Healing Approach) technique","March 31, 2020",,"https://ClinicalTrials.gov/show/NCT04328610"
132,"NCT04443348","Pre-op Pembro + Radiation Therapy in Breast Cancer","Not yet recruiting","No Results Available","Triple Negative Breast Cancer|Hormone Receptor Positive (HR+), HER2-negative Breast Cancer|Biopsy-proven, Positive Lymph Node(s)","Radiation: Radiation Therapy Boost|Drug: Pembrolizumab|Drug: Paclitaxel|Drug: Carboplatin|Drug: Cyclophosphamide|Drug: Doxorubicin","June 23, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04443348"
133,"NCT04281641","Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer","Recruiting","No Results Available","HER2-positive Breast Cancer","Diagnostic Test: TCHP","February 24, 2020","Shanghai Cancer Center, Fudan University, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04281641"
134,"NCT04273555","Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging","Not yet recruiting","No Results Available","HER2-positive Breast Cancer","Drug: [18F]-FDG","February 18, 2020","The University of Alabama at Birmingham, Birmingham, Alabama, United States","https://ClinicalTrials.gov/show/NCT04273555"
135,"NCT04288141","A Study to Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted Therapies","Recruiting","No Results Available","HER2-positive Breast Cancer","Other: Acquisition of blood samples and tumour tissue samples (biopsies)","February 28, 2020","Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom|Guy's Cancer Centre, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04288141"
136,"NCT04395508","An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic","Available","No Results Available","HER2-positive Breast Cancer","Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC)","May 20, 2020","MedStar Washington Hosp Center, Washington, District of Columbia, United States","https://ClinicalTrials.gov/show/NCT04395508"
137,"NCT04352777","Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer","Not yet recruiting","No Results Available","Metastatic Breast Cancer|Locally Advanced Breast Cancer|Hormone Receptor Positive Tumor","Drug: Abemaciclib|Drug: Fulvestrant|Drug: Aromatase Inhibitors","April 20, 2020","Duke University Medical Center, Durham, North Carolina, United States","https://ClinicalTrials.gov/show/NCT04352777"
138,"NCT04337658","Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer","Not yet recruiting","No Results Available","HER2-positive Breast Cancer","Drug: Pertuzumab|Drug: Trastuzumab|Drug: Fulvestrant|Drug: Capecitabine","April 8, 2020","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China","https://ClinicalTrials.gov/show/NCT04337658"
139,"NCT04330040","Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer","Recruiting","No Results Available","Ovarian Cancer|Breast Cancer","Drug: Olaparib","April 1, 2020","BLK Hospital, New Delhi, Delhi, India","https://ClinicalTrials.gov/show/NCT04330040"
140,"NCT04319510","Supportive Effects of Craniosacral Therapy for Female Patients With Breast Cancer and Their Partners","Not yet recruiting","No Results Available","Breast Cancer|Complementary Therapies","Procedure: Craniosacral therapy|Procedure: Craniosacral self-help group training|Procedure: Treatment as usal / wait list","March 24, 2020","Department of Internal and Integrative Medicine, Evang. Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen, Essen, NRW, Germany","https://ClinicalTrials.gov/show/NCT04319510"
141,"NCT04214288","A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer","Recruiting","No Results Available","Advanced ER-Positive HER2-Negative Breast Cancer","Drug: AZD9833|Drug: Fulvestrant","January 2, 2020","Research Site, Birmingham, Alabama, United States|Research Site, Long Beach, California, United States|Research Site, Canton, Ohio, United States|Research Site, Nashville, Tennessee, United States|Research Site, Wenatchee, Washington, United States|Research Site, Brasschaat, Belgium|Research Site, Charleroi, Belgium|Research Site, Gent, Belgium|Research Site, Haine-Saint-Paul, Belgium|Research Site, Leuven, Belgium|Research Site, Libramont-Chevigny, Belgium|Research Site, Namur, Belgium|Research Site, Besancon, France|Research Site, Clermont Ferrand, France|Research Site, Nantes, France|Research Site, Paris, France|Research Site, Saint Priest En Jarez, France|Research Site, Berlin, Germany|Research Site, Düsseldorf, Germany|Research Site, Essen, Germany|Research Site, Köln, Germany|Research Site, Lüneburg, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Kaposvár, Hungary|Research Site, Kecskemét, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pécs, Hungary|Research Site, Szeged, Hungary|Research Site, Bologna, Italy|Research Site, Meldola, Italy|Research Site, Milano, Italy|Research Site, Milan, Italy|Research Site, Monza, Italy|Research Site, Napoli, Italy|Research Site, Roma, Italy|Research Site, Umbria, Italy|Research Site, Mexico, Mexico|Research Site, Bydgoszcz, Poland|Research Site, Piła, Poland|Research Site, Rzeszów, Poland|Research Site, Skorzewo, Poland|Research Site, Warszawa, Poland|Research Site, Łódź, Poland|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Loures, Portugal|Research Site, Setúbal, Portugal|Research Site, Kazan, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Kursk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, A Coruña, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Caceres, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Pamplona, Spain|Research Site, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT04214288"
142,"NCT04278469","Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy","Recruiting","No Results Available","Early Hormone Receptor-positive Breast Cancer","Drug: Chemotherapy Drugs, Cancer","February 20, 2020","Samsung Medical Center, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT04278469"
143,"NCT04418089","Simvastatin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response and Tumor-Free Margin in Locally Advanced Breast Cancer","Completed","No Results Available","Breast Cancer|Chemotherapy Effect","Drug: Simvastatin 40mg|Drug: Placebo oral capsule","June 5, 2020","Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, DKI Jakarta, Indonesia","https://ClinicalTrials.gov/show/NCT04418089"
144,"NCT04355520","A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer","Not yet recruiting","No Results Available","HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer","Drug: TQ-B3525|Drug: Fulvestrant injection","April 21, 2020","Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China|Hunan Cancer Hospital, Changsha, Hunan, China|The First Hospital of Jilin university, Changchun, Jilin, China|Liaoning Cancer Hospital, Shenyang, Liaoning, China","https://ClinicalTrials.gov/show/NCT04355520"
145,"NCT04304924","Motivating to Exercise and Diet, and Educating to Healthy Behaviors After Breast Cancer","Not yet recruiting","No Results Available","Overweight or Obese Breast Cancer Patients","Other: The personalized telephone based intervention","March 12, 2020","Gustave Roussy, Villejuif, Val De Marne, France","https://ClinicalTrials.gov/show/NCT04304924"
146,"NCT04264468","Correlation Between Molecular Typing and Neoadjuvant Chemotherapy in Breast Cancer Patients Based on Mammaprint/Blueprint Test","Recruiting","No Results Available","Evaluation of the Value of Mammaprint Test Gene Variation in the Prediction of Neoadjuvant Chemotherapy for Breast Cancer","Combination Product: neoadjuvant chemotherapy","February 11, 2020","Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China","https://ClinicalTrials.gov/show/NCT04264468"
147,"NCT04236310","A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.","Not yet recruiting","No Results Available","Breast Cancer|HER2-positive Breast Cancer|ER-positive Breast Cancer","Drug: SHR6390|Drug: Anastrozole|Drug: Pyrotinib|Drug: Trastuzumab","January 22, 2020",,"https://ClinicalTrials.gov/show/NCT04236310"
148,"NCT04296370","A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation","Not yet recruiting","No Results Available","Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation","Drug: Fluzoparib; Apatinib|Drug: Fluzoparib|Drug: Physician's choice chemotherapy","March 5, 2020","Jiangsu HengRui Medicine Co., Ltd., Shanghai, China","https://ClinicalTrials.gov/show/NCT04296370"
149,"NCT04396665","Breast Cancer: Feasibility of an Educational Intervention","Enrolling by invitation","No Results Available","Women's Health: Neoplasm of Breast","Behavioral: Precam","May 20, 2020","University of Oviedo, Oviedo, Asturias, Spain","https://ClinicalTrials.gov/show/NCT04396665"
150,"NCT04426435","Effects a Honey Based Syrup on Blood Parameters in Patients With Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: honey based (HB) syrup","June 11, 2020","Shohaday-e- Tajrish Hospital, Tehran, Iran, Islamic Republic of","https://ClinicalTrials.gov/show/NCT04426435"
151,"NCT04334096","Long-term Improvement of Quality of Life in Breast Cancer Patients With Quality of Life Diagnosis and Therapy","Active, not recruiting","No Results Available","Quality of Life|Breast Cancer|Breast Neoplasms","Behavioral: quality of life pathway","April 6, 2020","Tumor Center Regensburg, Institute of Quality Management and Health Services Research of the University of Regensburg, Regensburg, Bavaria, Germany","https://ClinicalTrials.gov/show/NCT04334096"
152,"NCT04226222","Bringing of PET-TDM FDG in the Determination of the Characteristics of Primary Mammary Tumors TrIple Negatives","Recruiting","No Results Available","Breast Cancer","Diagnostic Test: TEP-TDM FDG","January 13, 2020","Institut de Cancerologie de L'Ouest, Saint-Herblain, France","https://ClinicalTrials.gov/show/NCT04226222"
153,"NCT04389216","Radiofrequency Ablation (RFA) in Breast Tumors","Recruiting","No Results Available","Breast Cancer Female","Device: Cool-tip electrode for Radiofrequency Ablation","May 15, 2020","Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital del Mar, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT04389216"
154,"NCT04435028","Ketotifen: as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy","Completed","No Results Available","Breast Cancer|Iron Chelation","Drug: Ketotifen 1 MG","June 17, 2020","Horus University, Damietta, Damiete Governonate, Egypt","https://ClinicalTrials.gov/show/NCT04435028"
155,"NCT04275661","Ketamine Versus Magnesium Sulphate as Adjuvants for ESPB in Breast Cancer Surgery","Recruiting","No Results Available","Analgesia|Breast Cancer","Procedure: Ultrasound (US) bi-level erector spinae block|Drug: levobupivacaine|Drug: Ketamine|Drug: Magnesium Sulfate","February 19, 2020","south Egypt Cancer Institute Assiut University, Assiut, Egypt","https://ClinicalTrials.gov/show/NCT04275661"
156,"NCT04428528","Pilot Study to Evaluate Photoacoustic Imaging for Characterizing Breast Masses and Breast Tumor Response to Neoadjuvant Chemotherapy Pilot Study to Evaluate Photoacoustic Imaging for Characterizing Breast Masses and Breast Tumor Response to Neoadjuvant Chemotherapy","Recruiting","No Results Available","Breast Cancer",,"June 11, 2020","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04428528"
157,"NCT04258085","Promoting Earlier Detection of Breast Cancer in Rwanda: Scaleup in the National Health Care System","Not yet recruiting","No Results Available","Breast Cancer|Benign Breast Disease","Other: Implementation of electronic medical record in districts implementing breast cancer screening|Other: Early diagnosis program combined with electronic medical record","February 6, 2020",,"https://ClinicalTrials.gov/show/NCT04258085"
158,"NCT04220203","Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer","Approved for marketing","No Results Available","HER2-positive Breast Cancer","Drug: Tucatinib|Drug: Capecitabine|Drug: Trastuzumab","January 7, 2020",,"https://ClinicalTrials.gov/show/NCT04220203"
159,"NCT04336917","Ultrasound Guided Rhomboid Intercostal and Subserratus Plane Block in Breast Cancer Surgeries","Recruiting","No Results Available","Breast Cancer Surgery|Postoperative Analgesia","Drug: Rhomboid Intercostal and Subserratus Plane Block with local anesthetic","April 7, 2020","Konya Education and Training Hospital, Konya, Turkey","https://ClinicalTrials.gov/show/NCT04336917"
160,"NCT04293796","Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB)","Recruiting","No Results Available","Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB","Procedure: Vacuum-assisted biopsy","March 3, 2020","Petr Krivorotko, Saint-Petersburg, Russian Federation","https://ClinicalTrials.gov/show/NCT04293796"
161,"NCT04350021","Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer","Recruiting","No Results Available","Breast Cancer Metastatic|Chemotherapy Effect","Drug: Capecitabine, Cyclophosphamide","April 16, 2020","Sahlgrenska University Hospital, Goteborg, Vastra Gotaland, Sweden","https://ClinicalTrials.gov/show/NCT04350021"
162,"NCT04245150","Assessing the Impact of the Microbiome on Breast Cancer Radiotherapy Toxicity","Recruiting","No Results Available","DCIS|Invasive Breast Cancer","Other: Stool sample|Other: Skin Swab Sample","January 28, 2020","Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT04245150"
163,"NCT04355858","Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer","Not yet recruiting","No Results Available","Breast Neoplasm","Drug: SHR7390|Drug: Famitinib|Drug: SHR3162|Drug: Pyrotinib|Drug: Capecitabine|Drug: SHR1210|Drug: Everolimus|Drug: Nab paclitaxel|Drug: SHR2554|Drug: SHR3680|Drug: SHR6390|Drug: SHR1701","April 21, 2020","Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04355858"
164,"NCT04249440","Systemic Treatment Preoperatively vs Postoperatively in HER2 Positive Early Breast Cancer","Completed","No Results Available","Breast Cancer|HER2|Preoperative Systemic Treatment","Procedure: Preoperative systemic treatment","January 31, 2020",,"https://ClinicalTrials.gov/show/NCT04249440"
165,"NCT04406779","The Frequency of Thyroid Diseases in Women With Breast Cancer","Completed","No Results Available","Breast Cancer|Thyroid Diseases","Device: thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies","May 28, 2020",,"https://ClinicalTrials.gov/show/NCT04406779"
166,"NCT04267796","Lifestyle Intervention for the Reduction of Breast Cancer Risk in Normal Weight Women","Recruiting","No Results Available","Breast Carcinoma","Other: Aerobic Exercise|Other: Dietary Intervention|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Other: Resistance Training","February 13, 2020","M D Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04267796"
167,"NCT04444882","Complications After Lumpectomy, Sentinel Node and Radiotherapy in Breast Cancer Patients and Physiotherapy Care","Not yet recruiting","No Results Available","Breast Neoplasm",,"June 24, 2020",,"https://ClinicalTrials.gov/show/NCT04444882"
168,"NCT04361240","Cardiotoxicity in Breast Cancer Patients Treated With Proton or Photon Radiotherapy: A RadComp Ancillary Study","Not yet recruiting","No Results Available","Breast Cancer|Cardiotoxicity","Radiation: Proton vs Photon Radiation","April 24, 2020","Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04361240"
169,"NCT04274933","A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy","Recruiting","No Results Available","Breast Cancer|Cancer","Drug: Venetoclax|Drug: Capecitabine","February 18, 2020","Joliet Oncology-Hematology Associates, LTD /ID# 215051, Joliet, Illinois, United States|Univ Kansas Med Ctr /ID# 215376, Kansas City, Kansas, United States|Massachusetts General Hospital /ID# 214833, Boston, Massachusetts, United States|Masonic Cancer Center /ID# 216101, Minneapolis, Minnesota, United States|Memorial Sloan Kettering Cancer Center /ID# 214886, New York, New York, United States|University of Pennsylvania /ID# 216357, Philadelphia, Pennsylvania, United States|Greenville Health System Cance /ID# 216059, Greenville, South Carolina, United States|Vanderbilt University Med Ctr /ID# 213852, Nashville, Tennessee, United States|Utah Cancer Specialists /ID# 215375, Salt Lake City, Utah, United States|Swedish Cancer Institute /ID# 216120, Seattle, Washington, United States|Universitaetsklinik Heidelberg /ID# 214679, Heidelberg, Baden-Wuerttemberg, Germany|Universitaetsklinikum Ulm /ID# 214678, Ulm, Thueringen, Germany|Charite Universitatsmedizin Berlin Campus Virchow Klinikum /ID# 215287, Berlin, Germany|Universitatsklinikum Tubingen /ID# 217021, Tuebingen, Germany|Pan American Center for Oncology Trials, LLC /ID# 216862, Rio Piedras, Puerto Rico|GCM Medical Group PSC - Hato Rey /ID# 216904, San Juan, Puerto Rico","https://ClinicalTrials.gov/show/NCT04274933"
170,"NCT04330339","Prolonged Nightly Fasting in Breast Cancer Survivors","Not yet recruiting","No Results Available","Fasting|Breast Cancer|Survivorship|Breast Cancer Recurrent","Behavioral: Fasting","April 1, 2020","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04330339"
171,"NCT04245176","Genetic Testing for All Breast Cancer Patients (GET FACTS)","Recruiting","No Results Available","Breast Cancer|Invasive Breast Cancer|in Situ Breast Cancer|Genetic Testing","Behavioral: Standard Genetic Counseling|Behavioral: Quantitative Genetic Counseling","January 28, 2020","Dana Farber Cancer Institute, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04245176"
172,"NCT04315233","Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics","Not yet recruiting","No Results Available","Metastatic Breast Cancer|Recurrent Ovarian Carcinoma","Drug: Ribociclib|Drug: Belinostat","March 19, 2020",,"https://ClinicalTrials.gov/show/NCT04315233"
173,"NCT04403984","Investigation of Genomic Alteration in Patients With Luminal A or Luminal B Subtypes","Recruiting","No Results Available","Breast Cancer",,"May 27, 2020","George Fountzilas, Athens, Greece","https://ClinicalTrials.gov/show/NCT04403984"
174,"NCT04316247","Demographic , Clinicopathological Characteristics and Survival of Breast Cancer","Not yet recruiting","No Results Available","Breast Carcinoma",,"March 20, 2020",,"https://ClinicalTrials.gov/show/NCT04316247"
175,"NCT04321135","Avanzando Juntas: Adapting an Evidence Based Weight Loss Program for Hispanic Breast Cancer Survivors","Recruiting","No Results Available","Breast Cancer|Gynecologic Cancer","Behavioral: Guided Lifestyle Program Intervention|Behavioral: Self-Guided Lifestyle Program (Control Arm)","March 25, 2020","Medical College of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT04321135"
176,"NCT04316169","Hydroxychloroquine (HCQ) in Combination With Abemaciclib and Endocrine Therapy in HR+/Her 2- Advanced Breast Cancer After a Lead in Dose Escalation Cohort of HCQ and Abemaciclib in Advanced Solid Tumors","Not yet recruiting","No Results Available","Solid Tumor|Advanced Breast Cancer","Drug: Abemaciclib|Drug: Hydroxychloroquine|Drug: Faslodex|Drug: Anastrazole|Drug: Letrozole","March 20, 2020",,"https://ClinicalTrials.gov/show/NCT04316169"
177,"NCT04414033","Bubble: A New VR-AI Way of Treatment for Hot Flashes in Women With Breast Cancer","Completed","No Results Available","Hot Flashes|Breast Cancer","Device: Bubble: A New VR-AI Way of Treatment for Hot Flashes","June 4, 2020","Bar Ilan University, Ramat Gan, Israel","https://ClinicalTrials.gov/show/NCT04414033"
178,"NCT04225858","Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy","Not yet recruiting","No Results Available","Breast Cancer|Triple Negative Breast Cancer|HER2-positive Breast Cancer|Sentinel Lymph Node","Procedure: Omission of sentinel lymph node biopsy","January 13, 2020",,"https://ClinicalTrials.gov/show/NCT04225858"
179,"NCT04301375","Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)","Not yet recruiting","No Results Available","Mammary Cancer","Drug: Pertuzumab and trastuzumab FDC subcutaneous|Drug: Paclitaxel|Drug: TDM1|Drug: Endocrine therapy|Procedure: Omission surgery","March 10, 2020","Hospital Clínic de Barcelona, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT04301375"
180,"NCT04252768","A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel","Not yet recruiting","No Results Available","Metastatic Breast Cancer","Drug: Eftilagimod Alpha|Drug: Paclitaxel","February 5, 2020",,"https://ClinicalTrials.gov/show/NCT04252768"
181,"NCT04246606","Concordance of the IHC4 Score Performed in Local or Central Laboratory to Endopredict in ER+/HER2- Breast Cancer","Recruiting","No Results Available","Breast Neoplasm Female","Diagnostic Test: IHC4 score","January 29, 2020","Centre Antoine Lacassagne, Nice, France","https://ClinicalTrials.gov/show/NCT04246606"
182,"NCT04256941","Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study","Recruiting","No Results Available","Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8","Drug: Abemaciclib|Drug: Anastrozole|Drug: Fulvestrant|Drug: Letrozole|Drug: Palbociclib|Drug: Ribociclib","February 5, 2020","M D Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04256941"
183,"NCT04235946","Feasibility Study of an Adapted and Supported Water Polo Program to Reduce Fatigue Related to Cancer and Improve Psychological and Social Recovery in Patients With Breast Cancer Remission","Not yet recruiting","No Results Available","Cancer Related Fatigue|Breast Cancer","Other: accompanied and adapted water polo program","January 22, 2020","Cercle des nageurs de Marseille, Marseille, France","https://ClinicalTrials.gov/show/NCT04235946"
184,"NCT04408560","Evaluation of the Efficacy of a Homeopathic Protocol in Patients With Non-metastatic Breast Cancer","Recruiting","No Results Available","Breast Cancer Female|Joint Pain","Drug: Rhus toxicodendron 9 CH + Ruta graveolens 5 CH (Homeopathic Granules)|Other: paracetamol (drug analgesic class1)","May 29, 2020","Philippe GUILBERT, Reims, France","https://ClinicalTrials.gov/show/NCT04408560"
185,"NCT04273542","Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening","Not yet recruiting","No Results Available","Breast Cancer Female|BRCA1 Mutation|BRCA2 Mutation","Other: liquid biopsy","February 18, 2020","Hôpital La Pitié Salpêtrière, Paris, Ile De France, France|Hôpital Tenon, Paris, Ile De France, France|Centre Jean PERRIN, Clermont-Ferrand, Puy De Dome, France|La Chataigneraie (Selimed 63), Beaumont, Puy De Dôme, France|Pôle Santé République, Clermont-Ferrand, Puy De Dôme, France","https://ClinicalTrials.gov/show/NCT04273542"
186,"NCT04424732","SBRT for Breast Cancer Oligometastases","Recruiting","No Results Available","Breast Neoplasm Malignant Female","Radiation: Stereotactic Body Radiotherapy","June 11, 2020","King Hussein Cancer Center, Amman, Jordan","https://ClinicalTrials.gov/show/NCT04424732"
187,"NCT04262804","A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC","Recruiting","No Results Available","Breast Cancer Metastatic","Drug: Margetuximab|Drug: Trastuzumab|Drug: Chosen Chemotherapy (Capecitabine)|Drug: Chosen Chemotherapy (Vinorelbine )|Drug: Chosen Chemotherapy (Gemcitabine )","February 10, 2020","National Taiwan University Hospital, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT04262804"
188,"NCT04332549","To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer","Withdrawn","No Results Available","Metastatic Breast Cancer|Locally Recurrent Cancer","Drug: PICS (Reconstitution Method 1 or 2)","April 2, 2020","SPARC Site 12, Visakhapatnam, Andhra Pradesh, India|SPARC Site 21, Ahmadabad, Gujarat, India|SPARC Site 22, Sūrat, Gujarat, India|SPARC Site 4, Bangalore, Karnataka, India|SPARC Site 10, Bangalore, Karnataka, India|SPARC Site 18, Bangalore, Karnataka, India|SPARC Site 13, Bangalore, Karnataka, India|SPARC Site 9, Aurangabad, Maharashtra, India|SPARC Site 8, Kolhāpur, Maharashtra, India|SPARC Site 2, Nagpur, Maharashtra, India|SPARC Site 1, Nagpur, Maharashtra, India|SPARC Site 17, Nagpur, Maharashtra, India|SPARC Site 3, Nashik, Maharashtra, India|SPARC Site 19, Nashik, Maharashtra, India|SPARC Site 15, Pune, Maharashtra, India|SPARC Site 16, Pune, Maharashtra, India|SPARC Site 5, Pune, Maharashtra, India|SPARC Site 11, Sāngli, Maharashtra, India|SPARC Site 20, Khorda, Orissa, India|SPARC Site 14, Madurai, Tamil Nadu, India|SPARC Site 7, Lucknow, Uttar Pradesh, India|SPARC Site 6, Gujrat, Vadodara, India","https://ClinicalTrials.gov/show/NCT04332549"
189,"NCT04291378","The DBCG Proton Trial: Photon Versus Proton Radiation Therapy for Early Breast Cancer","Not yet recruiting","No Results Available","Early Breast Cancer|Radiation Associated Cardiac Failure","Radiation: Proton versus photon radiation therapy","March 2, 2020","Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|The Danish Breast Cancer Cooperative Group, Copenhagen, Denmark|Rigshospitalet, Copenhagen, Denmark|Herlev Hospital, Herlev, Denmark|Naestved Hospital, Naestved, Denmark|Odense University Hospital, Odense, Denmark|Vejle Hospital, Vejle, Denmark","https://ClinicalTrials.gov/show/NCT04291378"
190,"NCT04265937","Screening of Genetic Susceptibility Genes for Breast Cancer Patients in Chinese Communities","Recruiting","No Results Available","Breast Cancer|Genetic Susceptibility",,"February 12, 2020","Zhen Hu, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04265937"
191,"NCT04313075","A Compassionate Use Study of Leronlimab in Breast Cancer","Available","No Results Available","Metastatic Triple-Negative Breast Carcinoma","Drug: Leronlimab","March 18, 2020",,"https://ClinicalTrials.gov/show/NCT04313075"
192,"NCT04238377","Post Mastectomy Pain Syndrome After Preoperative Stellate Ganglion Block for Breast Cancer Surgeries","Recruiting","No Results Available","Breast Cancer|Breast Pain","Procedure: Stellate Ganglion Block|Drug: Multimodal Analgesia","January 23, 2020","National Cancer Institute Cairo University, Cairo, Egypt","https://ClinicalTrials.gov/show/NCT04238377"
193,"NCT04334330","Palbociclib, Trastuzumab, Lapatinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China","Not yet recruiting","No Results Available","Breast Cancer|Brain Metastases","Drug: Palbociclib, Trastuzumab, Lapatinib and Fulvestrant","April 6, 2020","Shusen Wang, Guangzhou, Guangdong, China|State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT04334330"
194,"NCT04239105","Detection of Circulating Tumor Cells in Breast Cancer Patients Using a Novel Microfluidic and Raman Spectrum Device","Not yet recruiting","No Results Available","Breast Neoplasms|Circulating Tumor Cells","Device: Microfluidic and Raman spectrum","January 23, 2020",,"https://ClinicalTrials.gov/show/NCT04239105"
195,"NCT04442035","5-element Music Therapy on Patients With Breast Cancer","Completed","No Results Available","Breast Cancer Female|Quality of Life|Depression, Anxiety","Behavioral: 5-element music therapy","June 22, 2020","Guangdong Provincial Chinese medicine hospital, Guangzhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT04442035"
196,"NCT04289805","Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE)","Recruiting","No Results Available","Breast Neoplasm Malignant Female","Drug: Letrozole|Other: standard-stimulated cohort","February 28, 2020","CUB-Hôpital Erasme, Brussel, Belgium|CHC-Saint Vincent, Liège, Belgium|Centre Oscar Lambret, Lille, France|CHRU Lille, Lille, France","https://ClinicalTrials.gov/show/NCT04289805"
197,"NCT04446494","Identification and Preservation of Arm Lymphatics","Recruiting","No Results Available","Breast Cancer Related Lymphedema","Procedure: Identification and preservation of arm lymphatics (DEPART)","June 25, 2020","Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China","https://ClinicalTrials.gov/show/NCT04446494"
198,"NCT04277195","Developing a Diagnostic Tool to Predict Response to Chemotherapy","Active, not recruiting","No Results Available","Breast Cancer","Diagnostic Test: SPAG5 Assay","February 20, 2020","Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom","https://ClinicalTrials.gov/show/NCT04277195"
199,"NCT04373655","AXillary Surgery After NeoAdjuvant Treatment","Recruiting","No Results Available","Breast Cancer",,"May 4, 2020","Department of Gynecology and Obstetrics, University of Aachen, Aachen, Germany","https://ClinicalTrials.gov/show/NCT04373655"
200,"NCT04327063","MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery","Not yet recruiting","No Results Available","Malignant Neoplasm of Breast","Drug: Saline|Drug: Ropivacaine","March 30, 2020","Centre Jean Perrin, Clermont-Ferrand, France|Institut Curie, Paris, France|Hopital Tenon, Paris, France","https://ClinicalTrials.gov/show/NCT04327063"
201,"NCT04296942","BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)","Not yet recruiting","No Results Available","Breast Cancer|Triple Negative Breast Cancer|HER2+ Breast Cancer|Hormone Receptor Negative Breast Cancer|Metastatic Breast Cancer","Biological: Brachyury-TRICOM|Drug: Entinostat|Biological: M7824|Biological: Ado-trastuzumab emtansine","March 5, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT04296942"
202,"NCT04262219","Clinician Communication About Sexual Health","Recruiting","No Results Available","Breast Cancer","Behavioral: iShare","February 10, 2020","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04262219"
203,"NCT04282031","A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer","Not yet recruiting","No Results Available","Advanced Solid Tumor|Breast Neoplasms","Drug: BPI-1178|Drug: Fulvestrant|Drug: Letrozole","February 24, 2020","Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04282031"
204,"NCT04365569","Evaluating the Effectiveness of an Individualized Nutrition and Physical Activity Counseling Program","Not yet recruiting","No Results Available","Breast Cancer","Behavioral: Nutrition and physical activity counseling program","April 28, 2020","Cleveland Clinic Florida Weston, Case Comprehensive Cancer Center, Weston, Florida, United States","https://ClinicalTrials.gov/show/NCT04365569"
205,"NCT04303741","A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC","Recruiting","No Results Available","Breast Cancer","Drug: Camrelizumab|Drug: Apatinib|Drug: Eribulin","March 11, 2020","The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT04303741"
206,"NCT04265872","Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC","Not yet recruiting","No Results Available","Breast Cancer","Drug: Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis","February 12, 2020","Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas, United States","https://ClinicalTrials.gov/show/NCT04265872"
207,"NCT04215744","Nail Changes Associated With Chemotherapy and Prevention of Nail Pigmentation by Ice Water Immersion","Not yet recruiting","No Results Available","Breast Cancer","Behavioral: Ice water immersion","January 2, 2020","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT04215744"
208,"NCT04414202","Observational Study of Intra-operative Partial Irradiation of Invasive Ductal Breast Carcinomas With a Good Prognosis","Recruiting","No Results Available","Invasive Breast Cancer|Breast-conserving Surgery","Procedure: tumorectomy with axillary dissection (sentinel lymph node)|Radiation: per-operative partial irradiation","June 4, 2020","Icm Val D'Aurelle, Montpellier, Herault, France","https://ClinicalTrials.gov/show/NCT04414202"
209,"NCT04296929","The Effect of Complex Decongestive Physiotherapy on Sensory Parameters in Breast Cancer Related Lymphedema.","Recruiting","No Results Available","Lymphedema|Lymphedema of Upper Arm|Breast Cancer","Other: Complex Decongestive Physiotherapy","March 5, 2020","Hacettepe University, Ankara, Samanpazari, Turkey","https://ClinicalTrials.gov/show/NCT04296929"
210,"NCT04300790","Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients","Not yet recruiting","No Results Available","Breast Cancer","Drug: Alpelisib|Drug: Metformin|Drug: Fulvestrant","March 9, 2020",,"https://ClinicalTrials.gov/show/NCT04300790"
211,"NCT04300478","Appetite and Exercise in Breast Cancer Survivors","Recruiting","No Results Available","Overweight|Breast Cancer|Obesity","Behavioral: REx Condition First|Behavioral: Sedentary Control Condition First","March 9, 2020","Univeristy of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|University of Colorado Cancer Center, Denver, Colorado, United States","https://ClinicalTrials.gov/show/NCT04300478"
212,"NCT04276337","Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy","Active, not recruiting","No Results Available","HER2-positive Breast Cancer|Chemotherapy Effect|Circulating Tumor DNA","Diagnostic Test: LiquidSCAN(Trade Mark) / CancerSCAN(Trade Mark)","February 19, 2020","Samsung Medical Center, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT04276337"
213,"NCT04300283","Pre-operative Hypnosis to Prevent Side Effects After Surgery","Recruiting","No Results Available","Breast Cancer Surgery","Behavioral: Hypnosis","March 9, 2020","Oslo University Hospital, Oslo, Norway","https://ClinicalTrials.gov/show/NCT04300283"
214,"NCT04368442","Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation","Recruiting","No Results Available","Breast Cancer Metastatic",,"April 29, 2020","Samsung Medical Center, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT04368442"
215,"NCT04288089","A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer","Not yet recruiting","No Results Available","Receptors, Estrogen|Genes, Erbb-2|Breast Neoplasms","Drug: Palbociclib (75, 100, 125 milligram [mg])|Drug: H3B-6545 (300, 450 mg)","February 27, 2020","Florida Cancer Specialists, Sarasota, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Saint Luke's Cancer Institute, Saint Peters, Missouri, United States|Tennessee Oncology, Nashville, Tennessee, United States|Royal Marsden NHS Foundation Trust, London, United Kingdom|Christie NHS Foundation Trust, Manchester, United Kingdom|Velindre Cancer Centre, Whitchurch, United Kingdom","https://ClinicalTrials.gov/show/NCT04288089"
216,"NCT04398108","A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC","Not yet recruiting","No Results Available","HER2 Positive Metastatic Breast Cancer","Drug: Margetuximab Margetuximab-IV","May 21, 2020",,"https://ClinicalTrials.gov/show/NCT04398108"
217,"NCT04224272","A Study of ZW25 With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer","Recruiting","No Results Available","HER2+/HR+ Breast Cancer","Drug: ZW25|Drug: Palbociclib|Drug: Fulvestrant","January 13, 2020","Sarah Cannon Research Institute, Nashville, Tennessee, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|Hospital Universitario Vall d'Hebrón, Barcelona, Spain|Hospital Ruber Internacional, Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT04224272"
218,"NCT04228991","Hypofractionated LocoRegional Radiotherapy in Breast Cancer","Not yet recruiting","No Results Available","Breast Neoplasms|Radiotherapy|Lymphedema","Radiation: Locoregional radiation treatment - Conventional fractionation|Radiation: Locoregional radiation treatment - Hypofractionation","January 14, 2020","Juravinski Cancer Centre, Hamilton, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04228991"
219,"NCT04379414","YES Study - Newly Diagnosed/Metastatic Intervention","Not yet recruiting","No Results Available","Breast Cancer|Symptom, Behavioral","Behavioral: YES portal","May 7, 2020","Dana Farber Cancer Institute, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04379414"
220,"NCT04368468","Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC","Not yet recruiting","No Results Available","Triple Negative Breast Cancer","Other: biomarker evolution","April 29, 2020",,"https://ClinicalTrials.gov/show/NCT04368468"
221,"NCT04316117","Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study","Recruiting","No Results Available","Anatomic Stage IV Breast Cancer AJCC v8|Hormone Receptor Positive Breast Carcinoma|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8","Procedure: Computed Tomography|Other: Fludeoxyglucose F-18|Procedure: Positron Emission Tomography","March 20, 2020","Carle on Vermilion, Danville, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States","https://ClinicalTrials.gov/show/NCT04316117"
222,"NCT04335669","NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC","Recruiting","No Results Available","Breast Cancer|Triple Negative Breast Neoplasms","Drug: epirubicin, cyclophosphamide, paclitaxel, carboplatin|Drug: epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin","April 6, 2020","Södra Älvsborgs Hospital, Borås, Sweden|Gävle hospital, Department of Oncology, Gävle, Sweden|Sahlgrenska University Hospital, Department of Oncology, Göteborg, Sweden|Halmstad Hospital, Department of Surgery, Halmstad, Sweden|Ryhov Hospital, Jönköping, Sweden|Karlstad Hospital, Karlstad, Sweden|Linköping University Hospital, Linköping, Sweden|Skåne University Hospital, Department of Oncology, Malmö, Sweden|Capio S:t Göran Hospital, Department of Oncology, Stockholm, Sweden|Södersjukhuset, Department of Oncology, Stockholm, Sweden|Sundsvall hospital, Sundsvall, Sweden|Norrland University Hospital, Department of Oncology, Umeå, Sweden|Academical Hospital, Department of Oncology, Uppsala, Sweden|Västmanlands Hopsital Västerås, Västerås, Sweden|Växjö Hospital, Department of Oncology, Växjö, Sweden|Örebro University Hospital, Department of Oncology, Örebro, Sweden","https://ClinicalTrials.gov/show/NCT04335669"
223,"NCT04350398","Rehabilitation Through Hippotherapy for the Management of Women After Primary Treatment of Breast Cancer","Recruiting","No Results Available","Breast Cancer Female|Side Effects|Psychological Distress|Physical Disability","Other: Hippotherapy|Other: Conventional therapy","April 17, 2020","Institut Equiphoria, La Canourgue, France","https://ClinicalTrials.gov/show/NCT04350398"
224,"NCT04297267","A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant Chemotherapy","Recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Gemcitabine|Drug: Cisplatin","March 5, 2020","Cancer Hospital/ Institute, Fudan University, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04297267"
225,"NCT04351230","Abemaciclib With or Without T-DM1 for the Treatment of HER2-Positive Metastatic Breast Cancer","Not yet recruiting","No Results Available","Anatomic Stage IV Breast Cancer AJCC v8|HER2 Positive Breast Carcinoma|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8","Drug: Abemaciclib|Biological: Trastuzumab Emtansine","April 17, 2020","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Carle Cancer Center NCI Community Oncology Research Program, Urbana, Illinois, United States|Ochsner NCI Community Oncology Research Program, New Orleans, Louisiana, United States|Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT04351230"
226,"NCT04305834","Abemaciclib Monotherapy in Treating Older Patients With Hormone Receptor Positive Metastatic Breast Cancer","Recruiting","No Results Available","Anatomic Stage IV Breast Cancer AJCC v8|Hormone Receptor Positive Breast Carcinoma|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8","Drug: Abemaciclib|Other: Questionnaire Administration","March 12, 2020","City of Hope Medical Center, Duarte, California, United States","https://ClinicalTrials.gov/show/NCT04305834"
227,"NCT04408118","First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC","Not yet recruiting","No Results Available","Metastatic Breast Cancer|Advanced Breast Cancer|Triple Negative Breast Cancer","Drug: Atezolizumab|Drug: Paclitaxel|Drug: Bevacizumab","May 29, 2020","Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy|Istituto Oncologico Veneto IRCCS, Padova, Italy|Hospital Prof. Doutor Fernando da Fonseca EPE, Amadora, Portugal|Champalimaud Foundation, Lisbon, Portugal|Centro Hospitalar Universitário do Porto, Porto, Portugal|Hospital de Dénia-MarinaSalud, Dénia, Alicante, Spain|Hospital Universitario La Ribera, Alzira, Spain|Instituto de Oncología (IOB), Barcelona, Spain|Hospital Universitario Insular de Gran Canaria, Las Palmas De Gran Canaria, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Ruber Juan Bravo, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|MD Anderson Cancer Center, Madrid, Spain|Hospital Universitario Son Llàtzer, Palma De Mallorca, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Universitari Sant Joan de Reus, Reus, Spain|Hospital Universitario San Juan de Alicante, San Juan De Alicante, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Quirónsalud Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT04408118"
228,"NCT04303221","Effects of the Anchor System in the Postural Stability","Recruiting","No Results Available","Breast Cancer|Balance; Distorted","Other: Exercise","March 11, 2020","Medical School of Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil","https://ClinicalTrials.gov/show/NCT04303221"
229,"NCT04262518","Feasibility of Integrating the Outcomes4Me Smartphone Navigation Application Into the Care Management of Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer|Invasive Breast Cancer|Metastatic Breast Cancer|Breast Carcinoma|Metastatic Breast Carcinoma","Device: Outcomes4Me Mobile App","February 10, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04262518"
230,"NCT04291950","Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women","Not yet recruiting","No Results Available","Triple Negative Breast Cancer","Procedure: Needle core biopsy","March 2, 2020","University of Arizona Cancer Center, Tucson, Arizona, United States","https://ClinicalTrials.gov/show/NCT04291950"
231,"NCT04348747","Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer","Not yet recruiting","No Results Available","Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Malignant Neoplasm in the Brain|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8","Biological: Anti-HER2/HER3 Dendritic Cell Vaccine|Drug: Celecoxib|Biological: Pembrolizumab|Biological: Recombinant Interferon Alfa-2b|Drug: Rintatolimod","April 16, 2020","Roswell Park Cancer Institute, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT04348747"
232,"NCT04395989","An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.","Recruiting","No Results Available","TNBC - Triple-Negative Breast Cancer","Drug: A1: Pyrotinib with Capecitabine|Drug: A2: nab-paclitaxel|Drug: B1: everolimus with nab-paclitaxel|Drug: B2: nab-paclitaxel|Drug: C1: PD-1 with nab-paclitaxel and famitinib|Drug: C2: nab-paclitaxel|Drug: D1: VEGFR and nab-paclitaxel|Drug: D2: nab-paclitaxel|Drug: E1: Everolimus with nab-paclitaxel|Drug: E2: nab-paclitaxel","May 20, 2020","Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04395989"
233,"NCT04219072","Clinical Classification of Pain in Breast Cancer Survivors","Recruiting","No Results Available","Chronic Pain|Cancer Pain|Breast Cancer",,"January 6, 2020","KutahyaMSU, Kütahya, Kutahya Health Sciences University, Turkey","https://ClinicalTrials.gov/show/NCT04219072"
234,"NCT04365803","Histology VABB-Histology Post Surgery Pilot Project (BETTY Trial)","Recruiting","No Results Available","Breast Cancer","Procedure: vacuum-assisted breast biopsy","April 28, 2020","European Instituto of Oncology, Milan, Italy","https://ClinicalTrials.gov/show/NCT04365803"
235,"NCT04379024","Pilot Study of Effects of Duavee® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms","Recruiting","No Results Available","Focus of Study is Healthy Women at Risk for Breast Cancer","Drug: DUAVEE 0.45Mg-20Mg Tablet","May 7, 2020","University of Kansas Medical Center, Kansas City, Kansas, United States","https://ClinicalTrials.gov/show/NCT04379024"
236,"NCT04297384","Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice","Recruiting","No Results Available","Anatomic Stage IV Breast Cancer AJCC v8|Breast Carcinoma|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma","Other: Informational Intervention|Other: Quality-of-Life Assessment|Other: Survey Administration","March 5, 2020","Roswell Park Cancer Institute, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT04297384"
237,"NCT04436809","Sentinel Node Biopsy Alone or With Axillary Dissection After Primary Chemotherapy","Completed","No Results Available","Breast Neoplasm Female","Procedure: Sentinel Node Biopsy|Procedure: Axillary Dissection","June 18, 2020",,"https://ClinicalTrials.gov/show/NCT04436809"
238,"NCT04360941","PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer","Not yet recruiting","No Results Available","Triple Negative Breast Cancer|Locally Advanced Breast Cancer|Recurrent Breast Cancer|Metastatic Breast Cancer|ER+ Breast Cancer|HER2-positive Breast Cancer","Drug: Palbociclib|Drug: Avelumab","April 24, 2020","Royal Marsden NHS Foundation Trust, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04360941"
239,"NCT04233385","Myofascial Massage for Pain and Immobility Following Breast Cancer Surgery","Recruiting","No Results Available","Breast Cancer|Mastectomy; Lymphedema|Pain, Shoulder|Mobility Limitation","Other: Myofascial Massage|Other: Light Touch","January 18, 2020","MetroHealth Medical Center, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT04233385"
240,"NCT04241237","Concordance Between Liquid and Tissue Biopsy","Not yet recruiting","No Results Available","Breast Neoplasms","Procedure: Blood Draw","January 27, 2020","London Regional Cancer Program, London, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04241237"
241,"NCT04418219","A Breast Cancer Vaccine (SV-BR-1-GM) in Combination With Pembrolizumab for the Treatment of Persistent, Recurrent, or Metastatic Breast Cancer","Not yet recruiting","No Results Available","Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma|Refractory Breast Carcinoma","Drug: Cyclophosphamide|Biological: Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM|Biological: Pembrolizumab|Biological: Recombinant Interferon Alpha 2b-like Protein|Other: Questionnaire Administration|Other: Quality of Life Assessment","June 5, 2020","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04418219"
242,"NCT04259905","Pink Warrior 2: Teleconference-based Gaming Support","Recruiting","No Results Available","Breast Cancer|Physical Activity","Behavioral: Active video game teleconference support group|Behavioral: Standard support group + pedometer","February 7, 2020","The University of Texas Medical Branch, Galveston, Texas, United States","https://ClinicalTrials.gov/show/NCT04259905"
243,"NCT04445844","INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study","Not yet recruiting","No Results Available","Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Breast Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Triple-negative Breast Cancer","Biological: Pelareorep|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Biological: Retifanlimab","June 24, 2020","Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States","https://ClinicalTrials.gov/show/NCT04445844"
244,"NCT04305236","Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer","Not yet recruiting","No Results Available","Breast Neoplasm|Hormone Receptor Positive Breast Carcinoma","Drug: Abemaciclib|Drug: Fulvestrant","March 12, 2020","Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States","https://ClinicalTrials.gov/show/NCT04305236"
245,"NCT04304404","Risk Reduction Program for Women Having High Risk of Breast Cancer","Active, not recruiting","No Results Available","Cancer Screening|Early Detection of Cancer|Breast Cancer|Preventive Health Care|Health Behavior","Behavioral: Breast Cancer Risk Reduction Program","March 11, 2020","Akdeniz University, Antalya, Turkey","https://ClinicalTrials.gov/show/NCT04304404"
246,"NCT04425018","MARGetuximab Or Trastuzumab (MARGOT)","Not yet recruiting","No Results Available","Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer|HER2-positive Breast Cancer","Drug: Paclitaxel|Drug: Pertuzumab|Drug: Margetuximab|Drug: Trastuzumab","June 11, 2020","Dana Farber Cancer Institute, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04425018"
247,"NCT04270123","An EORTC Study Updating the QLQ-BR23 to BR45","Not yet recruiting","No Results Available","Cancer|Breast Cancer","Other: EORTC QLQ-BR45 questionnaire","February 17, 2020","Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, United Kingdom","https://ClinicalTrials.gov/show/NCT04270123"
248,"NCT04276272","D4 Choline Breast PET/CT","Not yet recruiting","No Results Available","HER2-negative Breast Cancer|ER Positive Breast Cancer|Metastatic Breast Cancer","Other: Imaging scan","February 19, 2020","Imperial College Healthcare NHS Trust/ Imperial College london, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04276272"
249,"NCT04448886","Sacituzumab Govitecan Vs Pembrolizumab In HR+ / HER2 - MBC","Not yet recruiting","No Results Available","Invasive Breast Cancer|Metastatic Breast Cancer|HR-Positive Breast Cancer|HER2-negative Breast Cancer","Drug: Pembrolizumab|Drug: Sacituzumab Govitecan","June 26, 2020","Dana Farber Cancer Institute, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04448886"
250,"NCT04265547","Family-Based Intervention Study of the Effects of Environmental Exposures on Breast Tissue Composition","Enrolling by invitation","No Results Available","Breast Cancer Risk","Behavioral: Breast Cancer Risk Reduction Household Intervention","February 11, 2020","Columbia University Mailman School of Public Health, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04265547"
251,"NCT04386629","Health Economy Register","Recruiting","No Results Available","Breast Neoplasms",,"May 13, 2020","Hämato-onkologischer Studienkreis am Klinikum Aschaffenburg, Aschaffenburg, Germany|Kliniken der Stadt Köln - Krankenhaus Holweide, Brustzentrum, Cologne, Germany|Kliniken Essen Mitte, Essen, Germany|Onkology Bethanien Frankfurt, Frankfurt, Germany|Mammazentrum Hamburg Am Krankenhaus Jerusalem, Hamburg, Germany|University Hospital, Mainz, Germany|University Hospital, Mannheim, Germany|University Hospital, München, Germany|Johanna Etienne Krankenhaus, Neuss, Germany|Praxisnetzwerk Hämatologie/ intern. Onkologie, Troisdorf, Germany","https://ClinicalTrials.gov/show/NCT04386629"
252,"NCT04290897","Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors","Not yet recruiting","No Results Available","Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Early-Stage Breast Carcinoma|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8","Drug: Anhydrous Enol-oxaloacetate|Other: Questionnaire Administration","March 2, 2020","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT04290897"
253,"NCT04245657","Factors Affecting Functionality in Breast Cancer Survivors","Recruiting","No Results Available","Breast Cancer|Breast Cancer Female|Breast Cancer Lymphedema|Breast Carcinoma in Situ|Hand Grasp|Pain, Shoulder","Other: Tissue Dielectric Constant Measurement|Other: Muscle strength measurement|Other: Hand-Grip Strength Measurement|Other: Pain Threshold Measurement|Other: International Physical Activity Questionnaire-Short Form (IPAQ-SF)|Other: Fatigue Impact Scale|Other: Disabilities of Arm, Shoulder and Hand Scale (DASH)|Other: Exercise Benefits/ Barriers Scale|Other: Beck Depression Scale","January 29, 2020","İzmir Çiğli State Training Hospital, İzmir, Çiğli, Turkey","https://ClinicalTrials.gov/show/NCT04245657"
254,"NCT04282122","Clinical Database of Safe Personalized Adjuvant Breast Radiotherapy Based on Individual Radiosensitivity","Recruiting","No Results Available","Breast Cancer","Radiation: Radiotherapy","February 24, 2020","Institut Régional du Cancer de Montpellier, Montpellier, Occ, France","https://ClinicalTrials.gov/show/NCT04282122"
255,"NCT04216576","A Study of the Use of Text Message Reminders to Take Palbociclib","Recruiting","No Results Available","Breast Cancer","Other: Paper Drug Diary|Other: OhMD APP","January 2, 2020","Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04216576"
256,"NCT04249622","Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer","Not yet recruiting","No Results Available","Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|HER2 Positive Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8","Other: Best Practice|Other: Questionnaire Administration|Drug: Rifaximin","January 31, 2020","Mayo Clinic in Florida, Jacksonville, Florida, United States","https://ClinicalTrials.gov/show/NCT04249622"
257,"NCT04272372","Lymphedema Treatment Registry","Not yet recruiting","No Results Available","Breast Cancer Lymphedema","Drug: Ketoprofen","February 17, 2020",,"https://ClinicalTrials.gov/show/NCT04272372"
258,"NCT04388384","Real-life Pan-HER-blockade With Neratinib","Recruiting","No Results Available","Breast Neoplasm","Drug: Neratinib","May 14, 2020","Medical Practice, Landshut, Bavaria, Germany|Medical Practice, Goslar, Lower Saxony, Germany","https://ClinicalTrials.gov/show/NCT04388384"
259,"NCT04261179","Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer","Not yet recruiting","No Results Available","Head Cancer|Neck Cancer|Melanoma|Breast Cancer","Drug: Lymphoseek|Drug: Nanocoll","February 7, 2020","Hospital Clínico y provincial de Barcelona, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT04261179"
260,"NCT04297020","Brain Health in Breast Cancer Survivors","Recruiting","No Results Available","Cognitive Impairment|Cognitive Function",,"March 5, 2020","University of California at Los Angeles, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT04297020"
261,"NCT04306003","ERAS in Autologous Breast Reconstruction: A Pilot RCT","Recruiting","No Results Available","Breast Cancer","Other: ERAS pathway|Other: Standard Perioperative Care","March 12, 2020","Juravinski Hospital, Hamilton, Ontario, Canada|St. Joseph's Healthcare, Hamilton, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04306003"
262,"NCT04251533","Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss Without PIK3CA Mutation","Recruiting","No Results Available","Triple Negative Breast Neoplasms","Drug: alpelisib|Drug: placebo|Drug: nab-paclitaxel","February 5, 2020","Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT04251533"
263,"NCT04429633","Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer","Recruiting","No Results Available","Cardiotoxicity|Breast Cancer|Prevention|Adjuvant|Trastuzumab","Drug: Candesartan","June 12, 2020","Samsung Medical Center, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT04429633"
264,"NCT04434404","Evaluation of the Cardioprotective Effect of L-carnitine and Silymarin in Patients Receiving Anthracycline Chemotherapy","Completed","No Results Available","Breast Cancer","Drug: L-Carnitine 500Mg Oral Tablet","June 16, 2020","Horus University, Damietta, Tanta City, Egypt","https://ClinicalTrials.gov/show/NCT04434404"
265,"NCT04293874","Adaptive Symptom Care Using Fish-Based Nutritional Directives Post Breast Cancer","Suspended","No Results Available","Fatigue|Depression|Pain|Sleep Disturbance|Stress|Survivorship|Breast Cancer|Dietary Habits","Behavioral: Personalized Meal Plan|Behavioral: Dietary Omega-3LC intervention","March 3, 2020","Hartford HealthCare Cancer Institue, Hartford, Connecticut, United States","https://ClinicalTrials.gov/show/NCT04293874"
266,"NCT04359420","What Are the Benefits and Harms of Risk Stratified Screening in the NHS Breast Screening Programme: Study Protocol","Active, not recruiting","No Results Available","Breast Cancer","Other: BC-Predict|Other: NHS Breast Screening Programme","April 24, 2020","Manchester University NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT04359420"
267,"NCT04343820","Delayed Breast Reconstruction by Prepectoral Implant After Lipo-preparation (RM2prepec)","Recruiting","No Results Available","Breast Cancer Female","Procedure: Breast reconstruction","April 13, 2020","Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain, France","https://ClinicalTrials.gov/show/NCT04343820"
268,"NCT04294225","Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer","Recruiting","No Results Available","Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Early-Stage Breast Carcinoma|Invasive Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8","Drug: Anastrozole|Drug: Letrozole","March 4, 2020","Mayo Clinic, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT04294225"
269,"NCT04249167","Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer","Recruiting","No Results Available","Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Breast Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8","Drug: Atezolizumab|Procedure: Cryosurgery|Drug: Nab-paclitaxel","January 30, 2020","Mayo Clinic in Florida, Jacksonville, Florida, United States","https://ClinicalTrials.gov/show/NCT04249167"
270,"NCT04357652","Contraception and Cervical and Breast Cancer Screening in Obese Versus Non-obese Women","Not yet recruiting","No Results Available","Obesity",,"April 22, 2020","Uhmontpellier, Montpellier, France","https://ClinicalTrials.gov/show/NCT04357652"
271,"NCT04345913","Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer","Not yet recruiting","No Results Available","Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma|Unresectable Breast Carcinoma","Drug: Copanlisib Hydrochloride|Drug: Eribulin Mesylate","April 15, 2020",,"https://ClinicalTrials.gov/show/NCT04345913"
272,"NCT04343807","Ultrasound Guided PECS Block for Reducing Opioid Consumption and Improving Patient Satisfaction Through Adequate Pain Control Following Breast Cancer Surgery.","Not yet recruiting","No Results Available","Breast Neoplasm Female|Pain, Postoperative|Pain|Analgesia|Anaesthesia|Breast Cancer","Procedure: PECS Block|Other: Control Group","April 13, 2020",,"https://ClinicalTrials.gov/show/NCT04343807"
273,"NCT04378816","A Patient-centered Continuous and Interdisciplinary Shared Decision Making Approach for Breast Cancer Rehabilitation","Recruiting","No Results Available","Shared Decision Making|Self-Efficacy for Decision Making","Other: Shared decision making support tool","May 7, 2020","Taipei Medical University Hospital, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT04378816"
274,"NCT04216472","Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations","Recruiting","No Results Available","Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Refractory Breast Carcinoma|Triple-Negative Breast Carcinoma","Drug: Alpelisib|Drug: Nab-paclitaxel","January 2, 2020","M D Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04216472"
275,"NCT04374747","Fruit and Vegetable Intervention in Lactating Women to Reduce Breast Cancer Risk","Recruiting","No Results Available","Breast Cancer Female|Inflammation|Postpartum Weight Retention|Diet, Healthy|Risk Reduction","Behavioral: Dietary Counseling","May 5, 2020","University of Massachusetts Amherst, Amherst, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04374747"
276,"NCT04333706","A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)","Not yet recruiting","No Results Available","Breast|Metastatic|Triple Negative|Cancer|Disseminated Tumor Cell","Drug: Capecitabine|Combination Product: Sarilumab 150mg or 200 mg plus Capecitabine|Combination Product: Sarilumab 150mg plus Capecitabine","April 3, 2020","UF Health, Gainesville, Florida, United States","https://ClinicalTrials.gov/show/NCT04333706"
277,"NCT04416087","Exercise and Tumor Blood Flow in Breast Cancer Patients","Recruiting","No Results Available","Cancer, Breast","Other: Exercise","June 4, 2020","Turku PET Centre, Turku, Finland","https://ClinicalTrials.gov/show/NCT04416087"
278,"NCT04230109","Sacituzumab Govitecan In TNBC","Not yet recruiting","No Results Available","Invasive Breast Cancer|Triple Negative Breast Cancer|ER-Negative Breast Cancer|PR-Negative Breast Cancer|HER2-negative Breast Cancer","Drug: Sacituzumab Govitecan","January 18, 2020","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital - North Shore Cancer Center, Danvers, Massachusetts, United States|Massachusetts General Hospital at Newton-Wellesley Hospital, Newton, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04230109"
279,"NCT04241341","Does Immediate Lymphatic Reconstruction Decrease the Risk of Lymphedema After Axillary Lymph Node Dissection","Recruiting","No Results Available","Breast Cancer Lymphedema","Procedure: Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction|Procedure: Axillary Lymph Node Dissection without Immediate Lymphatic Reconstruction|Other: quality-of-life questionnaires|Other: measured by arm volume","January 27, 2020","Memoral Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth (Consent Only), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (Consent Only), Montvale, New Jersey, United States|Memoral Sloan Kettering Westchester (Consent Only), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau (Consent only), Uniondale, New York, United States","https://ClinicalTrials.gov/show/NCT04241341"
280,"NCT04276493","Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab","Recruiting","No Results Available","Breast Cancer|Gastric Cancer|Gastroesophageal Junction Cancer","Biological: ZW25|Drug: Docetaxel|Biological: Tislelizumab|Drug: Capecitabine|Drug: Oxaliplatin","February 19, 2020","National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul Saint Mary's Hospital, Seoul, Korea, Republic of|Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT04276493"
281,"NCT04434040","Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC","Not yet recruiting","No Results Available","Breast Cancer|Triple Negative Breast Cancer|Residual Cancer|Circulating Tumor DNA","Drug: Atezolizumab|Drug: Ipatasertib","June 16, 2020","Dana-Farber Cancer Institute, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04434040"
282,"NCT04389424","Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast Cancer","Recruiting","No Results Available","Breast Cancer|Endocrine Therapy|Endocrine Therapy Adverse Reaction|Vitamin D Deficiency|Nutrition Disorders|Obesity","Drug: Tamoxifen|Drug: Exemestane|Drug: Anastrozole|Diagnostic Test: Basal|Diagnostic Test: Recurrence","May 15, 2020","Instituto Jalisciense de Cancerologia, Guadalajara, Jalisco, Mexico","https://ClinicalTrials.gov/show/NCT04389424"
283,"NCT04247763","Fast Food, Fatigue, and Inflammation","Completed","No Results Available","Breast Cancer","Other: Saturated Fat Meal|Other: Oleic Sunflower Oil Meal","January 30, 2020","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States","https://ClinicalTrials.gov/show/NCT04247763"
284,"NCT04440995","The Effects of Perioperative PECS Block During Robotic Breast Surgery and Breast Reconstruction","Not yet recruiting","No Results Available","Breast Neoplasm","Procedure: pectoral nerve block","June 22, 2020","Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT04440995"
285,"NCT04329819","Satisfaction and QUality of Life After Breast REconstruction","Completed","No Results Available","Mammaplasty|Breast Neoplasm Female",,"April 1, 2020","Institut de Cancerologie de l'Ouest, Saint-Herblain, France","https://ClinicalTrials.gov/show/NCT04329819"
286,"NCT04391296","Capsular Contracture After PMRT Using Prepectoral Versus Subpectoral Implant-based Breast Reconstruction: PREPER Trial","Not yet recruiting","No Results Available","Breast Cancer","Procedure: Arm I (Prepectoral), Arm II (Subpectoral)","May 18, 2020",,"https://ClinicalTrials.gov/show/NCT04391296"
287,"NCT04426136","A Prospective Cohort Study Comparing Disparity in Surgical Procedure (Wide Local Excision Only vs Any Other Surgery Procedures) Among the Elderly Breast Cancer Patients","Not yet recruiting","No Results Available","Breast Cancer|Elderly Patient|Wide Local Excision|Surgery|Survival Outcomes",,"June 11, 2020","Department of Breast Surgery,Peking Union Medical College Hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04426136"
288,"NCT04227613","Aspects of Breast-conserving Surgery","Enrolling by invitation","No Results Available","Breast Neoplasm|Cosmetic Outcome|Quality of Life",,"January 13, 2020","Central Hospital of Kristianstad, Kristianstad, Skåne, Sweden","https://ClinicalTrials.gov/show/NCT04227613"
289,"NCT04446624","Oxidative Stress, Anxiety and Depression in Breast Cancer Patients: Impact of Music Therapy","Completed","No Results Available","Breast Cancer|Depression, Anxiety|Oxidative Stress","Other: Music therapy intervention","June 25, 2020","Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy","https://ClinicalTrials.gov/show/NCT04446624"
290,"NCT04441827","Using Pranayama and Deep Breathing Exercises to Reduce Cancer-Related Fatigue and Insomnia During Radiotherapy","Completed","No Results Available","Breast Cancer|Fatigue|Insomnia","Other: breathing exercise","June 22, 2020","Ankara Yildirim Beyazıt University, Ankara, Turkey","https://ClinicalTrials.gov/show/NCT04441827"
291,"NCT04368702","CONFIRM: Magnetic Resonance Guided Radiation Therapy","Not yet recruiting","No Results Available","Gastric Cancer|Invasive Breast Cancer|in Situ Breast Cancer","Radiation: Viewray MRIdian® Linac","April 30, 2020","Brigham & Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04368702"
292,"NCT04420598","DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease","Active, not recruiting","No Results Available","Advanced Breast Cancer|HER2-positive Breast Cancer|Brain Metastases|Leptomeningeal Metastasis","Drug: Trastuzumab deruxtecan","June 9, 2020","Champalimaud Center for the Unknown, Lisbon, Portugal|Hospital da Luz, Lisbon, Portugal|Hospital Fernando Fonseca, Lisbon, Portugal|Hospital Santa Maria-Centro Hospitalario Lisboa Norte, Lisbon, Portugal|Instituto Português de Oncologia do Porto Francisco Gentil, EPE (IPO Porto), Porto, Portugal|Institut Català d'Oncologica ICO Badalona, Badalona, Spain|Hospital del Mar, Barcelona, Spain|Institut Oncologic Baselga-Hospital Quiron Salud Barcelona, Barcelona, Spain|Hospital San Pedro de Alcantara, Cáceres, Spain|Institut Catala d'Oncologia ICO Hospitalet, L'Hospitalet De Llobregat, Spain|Hospital Universitari Insular de Gran Canaria, Las Palmas De Gran Canaria, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|IOB- Complejo Hospitalario Ruber Juan Bravo, Madrid, Spain|MD Anderson Cancer Center, Madrid, Spain|Hospital Son Llatzer, Palma De Mallorca, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Consorcio Hospital General de Valencia, Valencia, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitario Migue Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT04420598"
293,"NCT04364347","Chemotherapy-induced Circadian Rhythm Disruption","Recruiting","No Results Available","Breast Neoplasms",,"April 28, 2020","Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of","https://ClinicalTrials.gov/show/NCT04364347"
294,"NCT04270136","Feasibility of Total Mastectomy in Ambulatory Care","Not yet recruiting","No Results Available","Breast Cancer|Mastectomy|Ambulatory Care","Procedure: total mastectomy","February 17, 2020","CHU Amiens, Amiens, France","https://ClinicalTrials.gov/show/NCT04270136"
295,"NCT04266249","CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","Recruiting","No Results Available","Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Invasive Breast Carcinoma|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8","Drug: Docetaxel|Procedure: Lumpectomy|Procedure: Mastectomy|Drug: Nab-paclitaxel|Drug: Paclitaxel|Biological: Pertuzumab|Radiation: Radiation Therapy|Biological: Trastuzumab|Biological: Trastuzumab Emtansine","February 12, 2020","University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Kingman Regional Medical Center, Kingman, Arizona, United States|Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|PCR Oncology, Arroyo Grande, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Stamford Hospital/Bennett Cancer Center, Stamford, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Nanticoke Memorial Hospital, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|Lewis Hall Singletary Oncology Center, Thomasville, Georgia, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Swedish Covenant Hospital, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Illinois CancerCare-Dixon, Dixon, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Joliet Oncology-Hematology Associates Limited, Joliet, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Genesis Cancer Center - Silvis, Silvis, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Mary Greeley Medical Center, Ames, Iowa, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|McFarland Clinic PC-Boone, Boone, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Genesis Medical Center - East Campus, Davenport, Iowa, United States|Genesis Cancer Care Institute, Davenport, Iowa, United States|Iowa Cancer Specialists, Davenport, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States|Trinity Regional Medical Center, Fort Dodge, Iowa, United States|McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States|McFarland Clinic PC-Marshalltown, Marshalltown, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Maine Center for Cancer Medicine-Kennebunk, Kennebunk, Maine, United States|Maine Center for Cancer Medicine-Scarborough, Scarborough, Maine, United States|Maine Center for Cancer Medicine-Topsham, Topsham, Maine, United States|Beverly Hospital, Beverly, Massachusetts, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Addison Gilbert Hospital, Gloucester, Massachusetts, United States|Winchester Hospital, Winchester, Massachusetts, United States|Ascension Providence Hospitals - Novi, Novi, Michigan, United States|Ascension Providence Hospitals - Southfield, Southfield, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, United States|Cox Cancer Center Branson, Branson, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Parkland Health Center - Farmington, Farmington, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Mercy Hospital South, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Mercy Hospital Washington, Washington, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Carson Tahoe Regional Medical Center, Carson City, Nevada, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|OptumCare Cancer Care at Seven Hills, Henderson, Nevada, United States|21st Century Oncology-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|Las Vegas Urology - Green Valley, Henderson, Nevada, United States|Las Vegas Urology - Pebble, Henderson, Nevada, United States|Urology Specialists of Nevada - Green Valley, Henderson, Nevada, United States|Las Vegas Urology - Pecos, Las Vegas, Nevada, United States|Desert West Surgery, Las Vegas, Nevada, United States|OptumCare Cancer Care at Oakey, Las Vegas, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Las Vegas Prostate Cancer Center, Las Vegas, Nevada, United States|Las Vegas Urology - Sunset, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|21st Century Oncology-Vegas Tenaya, Las Vegas, Nevada, United States|Ann M Wierman MD LTD, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|Las Vegas Urology - Cathedral Rock, Las Vegas, Nevada, United States|Las Vegas Urology - Smoke Ranch, Las Vegas, Nevada, United States|OptumCare Cancer Care at MountainView, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Northwest, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Town Center, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|21st Century Oncology-Fort Apache, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Southwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|University Cancer Center, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada-Pahrump, Pahrump, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Radiation Oncology Associates, Reno, Nevada, United States|New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire, United States|New Hampshire Oncology Hematology PA-Hooksett, Hooksett, New Hampshire, United States|The Cancer Institute of New Jersey Hamilton, Hamilton, New Jersey, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Somerville, New Jersey, United States|Lovelace Medical Center-Saint Joseph Square, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Lovelace Women's Hospital, Albuquerque, New Mexico, United States|Presbyterian Kaseman Hospital, Albuquerque, New Mexico, United States|Memorial Medical Center - Las Cruces, Las Cruces, New Mexico, United States|Presbyterian Rust Medical Center/Jorgensen Cancer Center, Rio Rancho, New Mexico, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|Montefiore Medical Center-Weiler Hospital, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Glens Falls Hospital, Glens Falls, New York, United States|University of Rochester, Rochester, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Cancer Centers of Southwest Oklahoma Research, Lawton, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Geisinger Cancer Services-Pottsville, Pottsville, Pennsylvania, United States|Community Medical Center, Scranton, Pennsylvania, United States|Geisinger Medical Oncology-Selinsgrove, Selinsgrove, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Wellmont Bristol Regional Medical Center, Bristol, Tennessee, United States|Regional Cancer Center at Indian Path Community Hospital, Kingsport, Tennessee, United States|Wellmont Holston Valley Hospital and Medical Center, Kingsport, Tennessee, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Parkland Memorial Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas, United States|Doctor's Hospital of Laredo, Laredo, Texas, United States|UT Southwestern Clinical Center at Richardson/Plano, Richardson, Texas, United States|Wellmont Medical Associates-Bristol, Bristol, Virginia, United States|Bon Secours Memorial Regional Medical Center, Mechanicsville, Virginia, United States|Bon Secours Saint Francis Medical Center, Midlothian, Virginia, United States|Bon Secours DePaul Medical Center, Norfolk, Virginia, United States|Southwest VA Regional Cancer Center, Norton, Virginia, United States|Bon Secours Maryview Medical Center, Portsmouth, Virginia, United States|Bon Secours Saint Mary's Hospital, Richmond, Virginia, United States|Bon Secours Cancer Institute at Reynolds Crossing, Richmond, Virginia, United States|Bon Secours Health Center at Harbour View, Suffolk, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Overlake Hospital Medical Center, Bellevue, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Valley Medical Center, Renton, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|ThedaCare Regional Cancer Center, Appleton, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Oconto Falls, Oconto Falls, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States","https://ClinicalTrials.gov/show/NCT04266249"
296,"NCT04329065","Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer","Not yet recruiting","No Results Available","Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8","Biological: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|Drug: Paclitaxel|Biological: Trastuzumab|Biological: Pertuzumab","April 1, 2020","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT04329065"
297,"NCT04443413","Assessing the Rate of Complications in X-Ray Therapy Versus Proton Beam Radiation Therapy After Breast Conserving Surgery or Mastectomy in Treating Patients With Breast Cancer","Recruiting","No Results Available","Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8","Radiation: Proton Beam Radiation Therapy|Other: Questionnaire Administration|Radiation: X-ray Therapy","June 23, 2020","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT04443413"
298,"NCT04348955","Interest of Touch-massage in Hospital Day Care","Recruiting","No Results Available","Breast Neoplasm Malignant Female","Behavioral: Women between 18 and 70 years old with an adjuvant breast cancer histologically characterized","April 16, 2020","Insitut de Cancérologie de l'Ouest, Angers, France|Insitut de Cancérologie de l'Ouest, Angers, France","https://ClinicalTrials.gov/show/NCT04348955"
299,"NCT04243837","LYT-100 in Healthy Volunteers and BCRL","Recruiting","No Results Available","Breast Cancer Related Lymphoedema|Lymphoedema","Drug: LYT-100|Other: Matching Placebo","January 28, 2020","Nucleus Network VIC, Melbourne, Victoria, Australia","https://ClinicalTrials.gov/show/NCT04243837"
300,"NCT04300829","Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients","Not yet recruiting","No Results Available","Breast Adenocarcinoma|Radiation Dermatitis|Radiation Toxicity","Drug: cicaderma + simple hygiene rules|Other: Simple hygiene rules and a maximum of one topical treatment","March 9, 2020","Institut Sainte-Catherine, Avignon, France|Institut Curie, Paris, France|Institut Curie, Saint-Cloud, France","https://ClinicalTrials.gov/show/NCT04300829"
301,"NCT04251507","VR Ultrasound Guided Breast Localization","Not yet recruiting","No Results Available","Breast Neoplasm Female","Device: Oculus Go Virtual Reality Goggles","February 5, 2020",,"https://ClinicalTrials.gov/show/NCT04251507"
302,"NCT04438577","Lidocaine Mucilage-ICG as an Optical Agent for Tumor Delineation During Breast-conserving Surgery","Not yet recruiting","No Results Available","Breast Cancer","Drug: Lidocaine mucilage-ICG","June 19, 2020","Shantou Central Hospital, Shantou, Guangdong, China","https://ClinicalTrials.gov/show/NCT04438577"
303,"NCT04330625","Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)","Not yet recruiting","No Results Available","Hyperglycemia Drug Induced","Biological: REMD-477","April 1, 2020",,"https://ClinicalTrials.gov/show/NCT04330625"
304,"NCT04309929","Description of the Analgesia Obtained With the Anesthesiological Protocols Currently Used in Breast Surgery","Completed","No Results Available","Breast Cancer","Drug: Analgesics","March 17, 2020","Azienda Ospedaliero Universitaria Careggi, Florence, Italy","https://ClinicalTrials.gov/show/NCT04309929"
305,"NCT04391543","BIOpsychosocial Approach of the CAncer-RElated FAtigue (BIOCARE FActory)","Not yet recruiting","No Results Available","Breast Cancer","Other: Experimental session","May 18, 2020",,"https://ClinicalTrials.gov/show/NCT04391543"
306,"NCT04437602","Added Value of Preoperative Contrast Enhanced Mammography in Staging of Malignant Breast Lesions","Not yet recruiting","No Results Available","Breast Cancer","Diagnostic Test: Contrast Enhanced Mammography (CEM)","June 18, 2020","Halland Hospital Halmstad, Halmstad, Sweden|Helsingborg Hospital, Helsingborg, Sweden|Central Hospital Kristianstad, Kristianstad, Sweden","https://ClinicalTrials.gov/show/NCT04437602"
307,"NCT04397419","Red Bull Energy Drink Intake After Autologous Microsurgical Breast Reconstruction","Recruiting","No Results Available","Breast Cancer","Dietary Supplement: Red Bull Energy Drink|Other: Still water","May 21, 2020","Klinik Pyramide am See, Zürich, Zurich, Switzerland","https://ClinicalTrials.gov/show/NCT04397419"
308,"NCT04371913","Personalized Second Chance Breast Conservation (PSCBC): A Two Center Prospective Phase II Clinical Study","Recruiting","No Results Available","Breast Cancer","Radiation: 600cGY x 5 fractions","May 1, 2020","Weill Cornell Medicine, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04371913"
309,"NCT04363892","Combined Optical and Infrared Imaging for Early Prediction of Erythema During Breast and Chestwall Radiotherapy","Not yet recruiting","No Results Available","Breast Cancer","Other: Optical and infrared imaging","April 27, 2020",,"https://ClinicalTrials.gov/show/NCT04363892"
310,"NCT04356209","Improving Theempowerment in Patients With Severe Breast Fibrosis Radio-induced Treated by Pravastatin : Benefit of e-PROs (Electronic "" Patient Reported Outcome "") on Breast-related Quality of Life","Not yet recruiting","No Results Available","Breast Cancer","Other: e-PRO Intervention|Drug: Pravastatin","April 22, 2020","ICM Val d'Aurelle, Montpellier, France","https://ClinicalTrials.gov/show/NCT04356209"
311,"NCT04257474","Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk","Recruiting","No Results Available","Breast Cancer","Behavioral: Self-Report Survey|Behavioral: Qualitative Interviews","February 6, 2020","Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|Moffitt Cancer Center, Tampa, Florida, United States","https://ClinicalTrials.gov/show/NCT04257474"
312,"NCT04253366","Clinical Investigation to Evaluate the Ability of MammoWave in Breast Lesions Detection","Not yet recruiting","No Results Available","Breast Cancer","Device: Clinical investigation device class IIa not marked CE","February 5, 2020","Istituto Clinico Humanitas, Rozzano, Milano, Italy|Azienda Ospedaliera Universitaria S. Martino Di Genova, Genova, Italy|Hospital Virgen de la Salud, Toledo, Spain","https://ClinicalTrials.gov/show/NCT04253366"
313,"NCT04397029","Assessing the Sensitivity of ""SureTouch™"" in Identifying Clinically Significant Masses in Women Undergoing Diagnostic and Screening Mammography","Recruiting","No Results Available","Breast Cancer","Device: SureTouch","May 21, 2020","George Washington University - Medical Faculty Associates, Washington, District of Columbia, United States","https://ClinicalTrials.gov/show/NCT04397029"
314,"NCT04424758","Testing Video Information About Mammography Screening","Recruiting","No Results Available","Breast Cancer","Other: Video information about mammography screening|Other: Video information about smart energy systems","June 11, 2020","University of Copenhagen, Section of General Practice, Copenhagen, Capital, Denmark","https://ClinicalTrials.gov/show/NCT04424758"
315,"NCT04350957","Low-dose Imaging Technique (LITE)","Not yet recruiting","No Results Available","Breast Cancer","Diagnostic Test: Low-dose Imaging","April 17, 2020",,"https://ClinicalTrials.gov/show/NCT04350957"
316,"NCT04348123","Interventional Program Educates, Identifies + Overcomes Barriers to Complete Screening Mammography","Not yet recruiting","No Results Available","Breast Cancer","Other: Survey|Behavioral: Education Session","April 15, 2020","Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT04348123"
317,"NCT04302441","A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy","Recruiting","No Results Available","Breast Cancer","Drug: Vinorelbine|Drug: Capecitabine","March 10, 2020","Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04302441"
318,"NCT04268134","Altering Lipids for Tolerance of Aromatase Inhibitor Therapy","Not yet recruiting","No Results Available","Breast Cancer","Dietary Supplement: Omega-3 fatty acid supplement","February 13, 2020","University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States","https://ClinicalTrials.gov/show/NCT04268134"
319,"NCT04258280","Improving Genetic Counseling for BRCA+ Mothers","Not yet recruiting","No Results Available","Breast Cancer","Behavioral: Education and counseling|Behavioral: Education","February 6, 2020",,"https://ClinicalTrials.gov/show/NCT04258280"
320,"NCT04257643","Aquatic Versus Land Based Exercise on Lymphedema Post Mastectomy","Completed","No Results Available","Breast Cancer","Other: aquatic based exercise.|Other: land-based exercise.","February 6, 2020","Cairo university., Cairo., Cairo, Egypt","https://ClinicalTrials.gov/show/NCT04257643"
321,"NCT04239716","Regional Anesthesia for Modified Radical Mastectomy With Axillary Lymph Node Dissection","Recruiting","No Results Available","Breast Cancer","Other: regional anesthesia","January 27, 2020","Tanta University, Faculty of Medicine, Tanta, Egypt","https://ClinicalTrials.gov/show/NCT04239716"
322,"NCT04225572","Physical Rehabilitation Evaluation and Optimal Physical Therapy (PRE-OPT)","Recruiting","No Results Available","Breast Cancer","Behavioral: Physical Therapy: Dependent on Patient's Needs","January 13, 2020","University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT04225572"
323,"NCT04441099","NBE-002 in Patients With Advanced Solid Tumors","Not yet recruiting","No Results Available","Advanced Solid Tumor|Advanced Cancer|Triple Negative Breast Cancer","Drug: NBE-002","June 22, 2020",,"https://ClinicalTrials.gov/show/NCT04441099"
324,"NCT04379570","Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy","Not yet recruiting","No Results Available","Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|HER2 Negative Breast Carcinoma|Hormone Receptor Positive Breast Carcinoma|Invasive Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8","Other: Educational Intervention|Other: Text Message-based Navigation Intervention|Behavioral: Motivational Interviewing|Other: Best Practice|Other: Questionnaire Administration|Other: Quality-of-Life Assessment","May 7, 2020",,"https://ClinicalTrials.gov/show/NCT04379570"
325,"NCT04372459","Online Psychosocial Cancer Screening, Monitoring and Stepped Treatment in Cancer Survivors","Not yet recruiting","No Results Available","Breast Cancer|Psychological Distress|Emotional Disorder","Behavioral: Online integrated and stepped psychosocial care|Behavioral: Usual psychosocial care","May 4, 2020",,"https://ClinicalTrials.gov/show/NCT04372459"
326,"NCT04390529","Immediate Breast Reconstruction Following Mastectomy (IRMA)","Recruiting","No Results Available","Breast Cancer Female","Other: quality-of-life questionnaire: BREAST-Q","May 15, 2020","Kantonsspital Baden, PD Dr. med. Cornelia Leo, Baden, Aargau, Switzerland|Tumor- und Brustzentrum ZeTuP, Dr. Véronique Dupont Lampert, St. Gallen, Saint Gallen, Switzerland|Kantonsspital Frauenfeld, Prof. Dr. med. Mathias K. Fehr, Frauenfeld, Thurgau, Switzerland|Ospedale Regionale Bellinzona e Valli, Dr. Begoña Lipp von Wattenwyl, Bellinzona, Ticino, Switzerland|Campus SLB Sonnenhof AG, Bern, Switzerland|Universitätsspital Zürich, Klinik für Gynäkologie, Zürich, Switzerland","https://ClinicalTrials.gov/show/NCT04390529"
327,"NCT04242277","Wide-field Optical Coherence Tomography Imaging of Excised Breast Tissue.","Not yet recruiting","No Results Available","Breast Cancer Female","Device: Investigational WF-OCT device","January 27, 2020","MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04242277"
328,"NCT04440683","Antler Plate on Preventing Mammary High-risk Lesions From Malignant Development","Recruiting","No Results Available","Breast Cancer Prevention",,"June 22, 2020","First Hospital of Jilin University, Changchun, Jilin, China","https://ClinicalTrials.gov/show/NCT04440683"
329,"NCT04257799","Lumpectomy Specimen Margin Evaluation With Tomography and Structured Light Imaging","Recruiting","No Results Available","Breast Cancer Female","Other: Structured Light Imaging (SLI) System","February 6, 2020","Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States","https://ClinicalTrials.gov/show/NCT04257799"
330,"NCT04447651","Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)","Not yet recruiting","No Results Available","Metastatic Breast Cancer|SF3B1 Gene Mutation|Spliceosome Mutation","Other: Recommendation for treatment with immunotherapy","June 25, 2020",,"https://ClinicalTrials.gov/show/NCT04447651"
331,"NCT04390685","Prevention of Breast Cancer-related Lymphedma With Tacrolimus","Recruiting","No Results Available","Lymphedema","Drug: Tacrolimus ointment","May 15, 2020","Sydvestjysk Sygehus, Esbjerg, Denmark|Department of Plastic and Reconstructive Surgery, Odense, Denmark|Sygehus Lillebælt Vejle, Vejle, Denmark","https://ClinicalTrials.gov/show/NCT04390685"
332,"NCT04320693","Expanded Access for IMMU-132","Approved for marketing","No Results Available","Metastatic Triple-Negative Breast Carcinoma","Drug: IMMU-132","March 25, 2020",,"https://ClinicalTrials.gov/show/NCT04320693"
333,"NCT04222790","A Multicenter, Double-blind, Randomized Controlled Phase II Clinical Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity","Not yet recruiting","No Results Available","Early Breast Cancer","Drug: monosialic gangliosides|Other: Placebo","January 10, 2020",,"https://ClinicalTrials.gov/show/NCT04222790"
334,"NCT04257162","HER2-PREDICT: Translational Study of Tumor Samples From DS8201-A-U301 and DS8201-A-U302 Trials.","Recruiting","No Results Available","Metastatic Breast Cancer","Other: Tumor and Blood sample collection","February 5, 2020","Hospital Clínic de Barcelona, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT04257162"
335,"NCT04274504","Osteopontin in Metastatic Breast Cancer Patients","Completed","No Results Available","Survival, Prosthesis","Diagnostic Test: Osteopontin","February 18, 2020","Mansoura University Oncology Center, Mansoura, Daqahliyah, Egypt","https://ClinicalTrials.gov/show/NCT04274504"
336,"NCT04390698","Opioid Free Anesthesia in Breast Cancer Surgery","Not yet recruiting","No Results Available","Opioid Free Anesthesia","Procedure: paravertebral block|Drug: opioid free anesthesia|Procedure: sham block|Procedure: opioid general anesthesia","May 15, 2020",,"https://ClinicalTrials.gov/show/NCT04390698"
337,"NCT04248608","Perioperative Analgesic Modalities for Breast Cancer Surgeries","Recruiting","No Results Available","Analgesia","Procedure: serratus plane block|Procedure: erector spinae block|Drug: Morphine Sulfate","January 30, 2020","Department of anesthesia and pain medicine. National Cancer Institute, Cairo, Egypt","https://ClinicalTrials.gov/show/NCT04248608"
338,"NCT04301011","Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors","Recruiting","No Results Available","Solid Tumor|Triple Negative Breast Cancer|Microsatellite Stable Colorectal Cancer","Biological: TBio-6517|Biological: Pembrolizumab","March 9, 2020","Mayo Clinic, Phoenix, Arizona, United States|Mayo Clinic, Jacksonville, Florida, United States|Sylvester Comprehensive Cancer Center / UMHC, Miami, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Mayo Clinic, Rochester, Minnesota, United States|The Billings Clinic, Billings, Montana, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04301011"
339,"NCT04292860","Reverse Axillary Mapping in Breast Radiation Treatment Planning","Not yet recruiting","No Results Available","Breast Cancer|Lymphedema",,"March 3, 2020",,"https://ClinicalTrials.gov/show/NCT04292860"
340,"NCT04400552","Perioperative Oral Nutrition Supplementation in Malnourished Surgical Cancer Patients","Recruiting","No Results Available","Cancer of Breast|Cancer Colon","Dietary Supplement: ONS Pre-op + ONS Post-op|Dietary Supplement: ONS Pre-op + ONS Post-op + ONS Post-op 3 months|Dietary Supplement: Usual intake Pre-op + ONS Post-op","May 22, 2020","International Medical University, Kuala Lumpur, Malaysia","https://ClinicalTrials.gov/show/NCT04400552"
341,"NCT04418115","Fatigue as a Late Effect in Breast Cancer Survivors - is Acupuncture a Treatment Option?","Not yet recruiting","No Results Available","Fatigue|Depression, Anxiety|Insomnia|Hot Flashes|Quality of Life","Other: Acupuncture; based on Tradidtional Chinese Medicine","June 5, 2020",,"https://ClinicalTrials.gov/show/NCT04418115"
342,"NCT04372862","Comparison Between Serratus Anterior Plane Block and Erector Spinae Plane Block for Mastectomy","Active, not recruiting","No Results Available","Breast Cancer Postoperative Pain","Procedure: Plane block","May 4, 2020","Suez Canal University, Ismailia, Egypt","https://ClinicalTrials.gov/show/NCT04372862"
343,"NCT04322331","Tumor Immune Mechanism of Axillary Lymph Node Metastasis in Early Luminal Type A Breast Cancer","Enrolling by invitation","No Results Available","Immune Microenvironment|Luminal A|Lymph Node Metastases","Other: no intervention","March 26, 2020","Peking university people's hospital, Beijing, China","https://ClinicalTrials.gov/show/NCT04322331"
344,"NCT04324346","Central Catheters Used for Chemotherapy in Women With Breast Cancer","Recruiting","No Results Available","Catheter Related Complications","Drug: FEC75 (or EC90) x 6|Drug: FEC100 + Taxotere (EC90 + Taxotere) 3+3|Drug: Paclitaxel","March 27, 2020","Onkologiska kliniken, Karolinska University Hospital, Danderyd Hospital, Stockholm, Sweden","https://ClinicalTrials.gov/show/NCT04324346"
345,"NCT04261387","LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients","Not yet recruiting","No Results Available","Radiation Dermatitis","Drug: LUT014 Gel","February 7, 2020","University Hospital Assuta Ashdod, Ashdod, Israel","https://ClinicalTrials.gov/show/NCT04261387"
346,"NCT04420871","Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients With Colorectal or Breast Cancer","Completed","No Results Available","Patient Participation","Drug: 150 mg of Xeloda®|Drug: 150 mg of capecitabine","June 9, 2020","Phase Ⅰ Clinical Research Center, Qingdao, Shandong, China","https://ClinicalTrials.gov/show/NCT04420871"
347,"NCT04303325","Effect of Esketamine on Postoperative Depression、Gut Microbiota、Bispectral Index Data of Depression Patients Undergoing Breast Cancer Operation (ESPOD-BI)","Not yet recruiting","No Results Available","Depression","Drug: Esketamine|Drug: Saline Solution","March 11, 2020","the First Hospital of China Medical University, Shenyang, Liaoning, China","https://ClinicalTrials.gov/show/NCT04303325"
348,"NCT04282967","Streaming Web-based Exercise At Home: A Pilot Study","Not yet recruiting","No Results Available","Prostate Cancer|Breast Cancer Female","Behavioral: Exercise","February 25, 2020","Cedars Sinai Medical Center, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT04282967"
349,"NCT04257396","Carbon-Fibre Accessory (CARA) for Supine Breast Positioning to Reduce Toxicity in Whole Breast Radiotherapy","Recruiting","No Results Available","Adjuvant Radiotherapy for Breast Cancer","Device: Carbon-Fibre Adjustable Reuseable Accessory (CARA)","February 6, 2020","BC Cancer, Vancouver, British Columbia, Canada","https://ClinicalTrials.gov/show/NCT04257396"
350,"NCT04290585","Technology and Health Communication in Improving Health Outcomes in Patients Scheduled for Mammography","Completed","No Results Available","Female Breast Carcinoma|Healthy Subject","Other: Questionnaire Administration|Behavioral: Telephone-Based Intervention","March 2, 2020","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04290585"
351,"NCT04395339","GM1 Prophylaxis for WBRT Related Cognitive Dysfunction","Recruiting","No Results Available","Brain Metastases|Radiotherapy Side Effect|Cognitive Impairment|Gangliosidosis, GM1|Breast Cancer","Drug: Monosialotetrahexosyl ganglioside (GM1)|Drug: Control","May 20, 2020","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT04395339"
352,"NCT04385563","A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.","Recruiting","No Results Available","HER2-positive Metastatic Breast Cancer","Drug: TQ-B211|Drug: Herceptin®|Drug: docetaxel","May 13, 2020","Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04385563"
353,"NCT04365114","Patient Outcomes From Second Film-readers and Test Threshold Relaxation in Breast Screening","Enrolling by invitation","No Results Available","Breast Cancer|Ductal Carcinoma in Situ","Diagnostic Test: Breast Screening Mammography with single reader|Diagnostic Test: Breast screening mammography with two readers|Diagnostic Test: Test threshold","April 28, 2020","Univesity of Warwick, Coventry, Warwickshire, United Kingdom","https://ClinicalTrials.gov/show/NCT04365114"
354,"NCT04340180","Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction","Not yet recruiting","No Results Available","Breast Benign Tumor|Breast Malignant Tumor","Drug: Standard of Care (SOC) gadolinium Breast MRI|Drug: reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.","April 9, 2020","The Kirklin Clinic, Birmingham, Alabama, United States","https://ClinicalTrials.gov/show/NCT04340180"
355,"NCT04252859","[18F]Fluoroestradiol Imaging of Invasive Lobular Carcinoma Using PET/CT","Not yet recruiting","No Results Available","Invasive Lobular Breast Carcinoma","Drug: [18F]Fluoroestradiol (FES) PET/CT","February 5, 2020",,"https://ClinicalTrials.gov/show/NCT04252859"
356,"NCT04248179","The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery.","Recruiting","No Results Available","Breast Cancer|Ductal Carcinoma in Situ","Drug: Ropivacaine injection|Drug: Saline 0.9%|Drug: Sufentanil and PONV prophylaxis","January 30, 2020","Department of Anaesthesiology and Intensive Care Medicine, Zealand University Hospital, Roskilde, Roskilde, Zealand Region, Denmark","https://ClinicalTrials.gov/show/NCT04248179"
357,"NCT04397744","Unidas Por Vida y Salud: Increasing Breast and Cervical Cancer Screening in El Paso","Completed","No Results Available","Breast Cancer|Cervical Cancer","Behavioral: Unidas por Vida y Salud prevention program","May 21, 2020","The University of Texas Health Science Center at Houston, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04397744"
358,"NCT04426019","Using a Lay Health Worker Program to Increase Breast and Cervical Cancer Screening in Low-Income Hispanic Women","Completed","No Results Available","Breast Cancer|Cervical Cancer","Behavioral: CLS Intervention|Behavioral: No CLs intervention","June 11, 2020","The University of Texas Health Science Center at Houston, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04426019"
359,"NCT04335409","Pneumonitis After Radiotherapy of Breast or Lung Cancer","Not yet recruiting","No Results Available","Breast Cancer|Lung Cancer","Diagnostic Test: Questionnaire|Other: Mobile Application","April 6, 2020",,"https://ClinicalTrials.gov/show/NCT04335409"
360,"NCT04348188","Study of the Effectiveness of Supervised vs. Non-Supervised Therapeutic Exercise in Cancer Patients","Not yet recruiting","No Results Available","Breast Cancer|Colon Cancer","Behavioral: Education program on healthy habits","April 16, 2020","Hospital Universitario Infanta Leonor, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04348188"
361,"NCT04433494","A Study of TY-302 in Patients With Advanced Solid Tumors","Not yet recruiting","No Results Available","Breast Cancer|Solid Tumor","Drug: TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mg","June 16, 2020",,"https://ClinicalTrials.gov/show/NCT04433494"
362,"NCT04418856","The Effects of Light Therapy to Treat Cancer-related Side Effects","Not yet recruiting","No Results Available","Breast Cancer|Circadian Rhythms|Fatigue|Sleep Disturbance|Cognitive Impairment|Inflammatory Response|Depression","Device: Light Glasses (Experimental)|Device: Light Glasses (Comparison)","June 5, 2020",,"https://ClinicalTrials.gov/show/NCT04418856"
363,"NCT04273464","Breast Reconstruction With Autologous Tissue: Microsurgery or Fat Grafting?","Active, not recruiting","No Results Available","Breast Cancer|Mammaplasty","Procedure: Brava-group|Procedure: DIEP-group","February 18, 2020","Telemark Hospital, Skien, Telemark, Norway","https://ClinicalTrials.gov/show/NCT04273464"
364,"NCT04341129","Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)","Not yet recruiting","No Results Available","Breast Neoplasms|Breast Diseases|Breast Fibroadenoma|Breast Cancer","Drug: Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine)","April 10, 2020",,"https://ClinicalTrials.gov/show/NCT04341129"
365,"NCT04218149","Serratus Plane Block vs Erector Spinae Plane Block on Postoperative Analgesia in Patients Undergoing Unilateral Breast Surgery","Completed","No Results Available","Breast Cancer|Postoperative Pain","Drug: Bupivacaine Injection","January 6, 2020","SBÜ Şişli Hamidiye Etfal Eğitim ve Araştırma Hastanesi, Istanbul, Turkey","https://ClinicalTrials.gov/show/NCT04218149"
366,"NCT04342546","Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction","Not yet recruiting","No Results Available","Breast Cancer|Capsular Contracture Associated With Breast Implant","Device: NovaGray RILA Breast® test","April 13, 2020","Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Institut Paoli Calmette, Marseille, France|Institut du Cancer de Montpellier, Montpellier, France|Hôpital Tenon, Paris, France|Institut de Cancérologie de l'Ouest, Saint-Herblain, France","https://ClinicalTrials.gov/show/NCT04342546"
367,"NCT04303715","No Axillary sUrgical Treatment In Clinically Lymph Node Negative Patients After UltraSonography","Not yet recruiting","No Results Available","Breast Cancer|Sentinel Lymph Node","Procedure: No SLNB|Procedure: SLNB","March 11, 2020","Seoul National University Hospital, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT04303715"
368,"NCT04350411","Comparison of PEAK PlasmaBlade™ to Conventional Diathermy in Abdominal Based Free Flap Breast Reconstruction","Completed","No Results Available","Breast Reconstruction|Breast Cancer","Device: Conventional diathermy|Device: PEAK PlasmaBlade™","April 17, 2020","Mid Essex NHS trust, Chelmsford, Essex, United Kingdom","https://ClinicalTrials.gov/show/NCT04350411"
369,"NCT04297007","Pectoral Nerve Block Type-II and Rhomboid Intercostal Block for Pain Management Following Mastectomy Surgery","Recruiting","No Results Available","Breast Cancer|Breast Neoplasms|Breast Diseases|Breast Fibroadenoma","Other: PECS block|Other: Rhomboid intercostal block","March 5, 2020","Istanbul Medipol University Hospital, Istanbul, Bagcilar, Turkey","https://ClinicalTrials.gov/show/NCT04297007"
370,"NCT04221607","An Intimacy Intervention for Couples Completing Breast or Prostate Cancer","Recruiting","No Results Available","Sexual Dysfunction|Breast Cancer|Prostate Cancer","Other: Sensate Focus exercise","January 9, 2020","Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States","https://ClinicalTrials.gov/show/NCT04221607"
371,"NCT04435639","Using an Adjustable Compression Garment for Secondary Upper Limb Lymphoedema","Not yet recruiting","No Results Available","Lymphedema of Upper Arm","Device: Manual lymph drainage & adjustable compression sleeve.|Device: Control Manual Lymphatic drainage & Coban compression bandage..","June 17, 2020",,"https://ClinicalTrials.gov/show/NCT04435639"
372,"NCT04343950","SMS Messaging as a Tool to Improve Cancer Screening Programs","Not yet recruiting","No Results Available","Mass Screening|Colorectal Cancer|Breast Cancer","Behavioral: SMS reminders to enhance colorectal cancer screening|Behavioral: SMS reminders to return the fecal immunochemical test at the pharmacy in CRC screening:|Behavioral: Invitation by SMS to previous participants in breast cancer screening:","April 14, 2020",,"https://ClinicalTrials.gov/show/NCT04343950"
373,"NCT04389281","X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma","Not yet recruiting","No Results Available","Advanced Cancer","Combination Product: X-PACT","May 15, 2020",,"https://ClinicalTrials.gov/show/NCT04389281"
374,"NCT04246671","Phase 1/2 Trial of Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients","Not yet recruiting","No Results Available","Breast Cancer|Gastric Cancer|Cancer","Biological: TAEK-VAC-HerBy","January 29, 2020",,"https://ClinicalTrials.gov/show/NCT04246671"
375,"NCT04261829","AFT: Introduction of a Full Breast Reconstructive Method","Not yet recruiting","No Results Available","Breast Cancer|Reconstructive Surgery|Breast Reconstruction","Procedure: Autologous Fat Transfer","February 10, 2020",,"https://ClinicalTrials.gov/show/NCT04261829"
376,"NCT04349527","Comparison of the Cosmetic Results, Quality of Life and Patient Satisfaction Achieved With Round-block and Retroglandular Oncoplastic Breast Conserving Surgeries","Recruiting","No Results Available","Breast Cancer|Quality of Life|Patient Satisfaction","Procedure: Round-block Oncoplastic Breast Conserving Surgeries|Procedure: Retroglandular Oncoplastic Breast Conserving Surgeries","April 16, 2020","National Institute of Oncology, Budapest, Hungary","https://ClinicalTrials.gov/show/NCT04349527"
377,"NCT04262180","Physical Activity Promotion for Breast and Endometrial Cancer Survivors","Not yet recruiting","No Results Available","Physical Activity|Breast Cancer Survivors|Endometrial Cancer Survivors","Other: Base intervention-Fitbit with EHR integration|Other: Coaching Calls|Other: Online Gym","February 10, 2020","Department of Preventative Medicine, Northwestern University, Chicago, Illinois, United States|Department of Kinesiology, University of Wisconsin, Madison, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT04262180"
378,"NCT04256512","Cryotherapy to Prevent Taxane-induced Sensory Neuropathy of the Hands and Feet","Recruiting","No Results Available","Breast Cancer|Peripheral Neuropathy|Chemotherapy-induced Peripheral Neuropathy","Device: Elasto Gel® Therapy Mittens and Foot Wraps","February 5, 2020","Mayo Clinic in Florida, Jacksonville, Florida, United States","https://ClinicalTrials.gov/show/NCT04256512"
379,"NCT04407611","Scalable Communication Modalities for Returning Genetic Research Results","Not yet recruiting","No Results Available","Hereditary Breast and Ovarian Cancer","Behavioral: Online modality|Behavioral: Genetic counselor follow-up","May 29, 2020",,"https://ClinicalTrials.gov/show/NCT04407611"
380,"NCT04356235","Examining and Comparing the Temporal Changes and Results of Cosmetic, Quality of Life and Patient Satisfaction Achieved With Immediate and Delayed-immediate Implant-based Breast Reconstruction Procedures and Contralateral Symmetrization Techniques","Recruiting","No Results Available","Mastectomy; Lymphedema|Breast Cancer|Quality of Life","Procedure: A: expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction|Procedure: B: expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling|Procedure: C: expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation|Procedure: D: expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation|Procedure: E: unilateral simple mastectomy|Procedure: F: after bilateral SSM, ASM, NSM, expander-implant exchange","April 22, 2020","National Institute of Oncology, Budapest, Hungary","https://ClinicalTrials.gov/show/NCT04356235"
381,"NCT04214210","The DIALOGUE Study: Swiss-Korean Billateral Collaboration","Not yet recruiting","No Results Available","Hereditary Cancer|Breast Cancer|Ovarian Cancer","Other: Adapted Family Gene Toolkit|Other: Targeted intervention","January 2, 2020","University Hospital Basel, Basel, Switzerland|Istituto Oncologico della Zvizzera Italiana, Bellinzona, Switzerland|Universitatklinik fur Medizinische Onkologie, Inselspital, Bern, Switzerland|Unite d'Oncogenetique et de Prevention des Cancers, Geneva, Switzerland","https://ClinicalTrials.gov/show/NCT04214210"
382,"NCT04234620","Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .","Not yet recruiting","No Results Available","Melanoma|Lung Cance|Breast Cancer","Drug: Toripalimab injection","January 21, 2020","Beijing Cancer Hospital, Beijing, Beijing, China|Cancer Hospital Chinese Academy of Medical Science, Beijing, China|The first affiliated Hospital of Jinlin Universtiy, Changchun, China|Hunan cancer hospital, Changsha, China|Xiangya Hospital Central South University, Changsha, China|Chongqing Haijiya Cancer Hospital, Chongqing, China|Fujian province cancer hospital, Fuzhou, China|Zhejiang cancer hospital, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Qilu Hospital of Shandong university, Jinan, China|Shandong province cancer hospital, Jinan, China|Affiliated Cancer Hospital of Guangxi Medical university, Nanjing, China|Najing Drum Tower Hospital, Nanjing, China|Fudan University Shanghai Cancer Center, Shanghai, China|Shanxi Bethune Hopital, Shanxi, China|The fouth Hospital of Hebei Medical University, Shijiazhuang, China|The Second affiliated Hospital of Suzhou Universtiy, Suzhou, China|Tianjin Medical University cancer institute & Hospital, Tianjin, China|Hubei cancer hospital, Wuhan, China|Tongji Medical College of Huazhong University of Science & Technology, Wuhan, China|Wuhan Union Hospital, Wuhan, China|The first affiliated Hospital of Xiamen Universtiy, Xiamen, China|Yinchuan Lingke Internet Hosipital, Yinchuan, China|Affiliated Hopital of Guangdong Medical University, Zhanjiang, China|Henan cancer hospital, Zhengzhou, China","https://ClinicalTrials.gov/show/NCT04234620"
383,"NCT04367467","Effect of PARP Inhibitors on Glomerular Filtration Rate","Active, not recruiting","No Results Available","Solid Tumor|Ovarian Cancer|Breast Cancer","Other: Kidney Function Test","April 29, 2020","University of Pennsylvania, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04367467"
384,"NCT04432857","AN0025 and Pembrolizumab Combination in Advanced Solid Tumors","Not yet recruiting","No Results Available","Triple-negative Breast Cancer|NSCLC, Squamous or Non-Squamous|Urothelial Carcinoma of the Bladder|Microsatellite Stable (MSS) Colorectal Cancer (CRC)|Cervical Cancer","Drug: AN0025|Drug: Pembrolizumab","June 16, 2020",,"https://ClinicalTrials.gov/show/NCT04432857"
385,"NCT04239560","Preventive Effect of Boron-based Gel on Radiation Dermatitis","Completed","No Results Available","Radiodermatitis","Drug: Boron-based Gel (Fibore)|Drug: Placebos","January 27, 2020","Shahid Madani Medical & Training Hospital - Department of Radiotherapy, Tabriz, East Azarbaijan, Iran, Islamic Republic of","https://ClinicalTrials.gov/show/NCT04239560"
386,"NCT04349111","An Efficacy Study of the Xoft® Axxent® eBx® IORT System® ""Lite""","Not yet recruiting","No Results Available","Invasive Ductal Carcinoma|Ductal Carcinoma In Situ","Radiation: Intra-operative Radiation Therapy - IORT","April 16, 2020",,"https://ClinicalTrials.gov/show/NCT04349111"
387,"NCT04330716","Genetic Testing for Breast, Ovarian, Pancreatic and Prostate Cancers","Not yet recruiting","No Results Available","Breast Cancer|Ovarian Cancer|Pancreatic Cancer|Metastatic Prostate Cancer","Behavioral: In Person Counseling|Behavioral: Educational Video","April 1, 2020","Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital, Weymouth, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04330716"
388,"NCT04332653","NT-I7 (Hyleukin-7) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors","Recruiting","No Results Available","Any Advanced Solid Tumors|Triple Negative Breast Cancer|Non Small Cell Lung Cancer|Small Cell Lung Cancer|Microsatellite Stable Colorectal Cancer|Pancreatic Cancer","Drug: NT-I7|Drug: Pembrolizumab","April 3, 2020","MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04332653"
389,"NCT04266353","Effect of Resveratrol on Serum IGF2 Among African American Women","Active, not recruiting","No Results Available","Chemoprevention","Dietary Supplement: Resveratrol (RSV)","February 12, 2020","Loma Linda University Cancer Center, Loma Linda, California, United States","https://ClinicalTrials.gov/show/NCT04266353"
390,"NCT04439175","Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)","Active, not recruiting","No Results Available","Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma","Drug: Taselisib","June 19, 2020","ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04439175"
391,"NCT04338334","Effectiveness of Cohesive Bandage on Axillary Web Syndrome After","Recruiting","No Results Available","Axillary Web Syndrome","Other: Manual drainage & arm therapeutic exercise|Other: Cohesive bandaging & arm therapeutic exercise","April 8, 2020","María Torres-Lacomba, Alcalá De Henares, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04338334"
392,"NCT04230941","Memory and Attention Adaptation Training-Geriatrics (MAAT-G)","Not yet recruiting","No Results Available","Cancer-related Problem/Condition|Cognitive Impairment","Behavioral: MAAT-G","January 18, 2020",,"https://ClinicalTrials.gov/show/NCT04230941"
393,"NCT04227990","Plinabulin iv Solution in Prevention of TAC Induced Neutropenia","Completed","No Results Available","Chemotherapy-induced Neutropenia","Drug: Plinabulin|Drug: Pegfilgrastim|Drug: Docetaxel, doxorubicin, and cyclophosphamide (TAC)","January 14, 2020","Cancer Center of Guangzhou Medical University Breast Oncology, Guangzhou, Guangzhou, China|Harbin Medical University Cancer Hospital, Harbin, Harbin, China|Fourth Hospital of Hebei Medical University Breast cancer department, Shijiazhuang, Hebei, China|China-Japan Union Hospital of Jilin University Tumor department of Hematology, Changchun, Jilin, China|Liaoning Cancer Hospital & Institute, Shenyang, Shenyang, China|Dnipropetrovsk City Multifunctional Hospital #4 Oncology Department, Dnepropetrovsk, Ukraine|Prykarpatskiy Regional Oncological Center, Ivano-Frankivs'k, Ukraine|""V.T. Zaycev Institute of General and Urgent Surgery NAMS of Ukraine Dept. of Oncology, Kharkiv, Ukraine|Public Institution Kryvyi Rih Oncology Center, Krivoy Bereg, Ukraine|Kirovograd Regional Oncological Center, Kropyvnytskyi, Ukraine|Odessa regional clinical hospital Thoracic Surgery Department Academician Zabolotnoho, Odessa, Ukraine","https://ClinicalTrials.gov/show/NCT04227990"
394,"NCT04440930","White Tea for Prevention of Chemotherapy Induced Mucositis","Not yet recruiting","No Results Available","Oral Mucositis","Other: White tea|Other: Salt water with soda","June 22, 2020","Department of Oncology, Vejle Hospital, Vejle, Denmark","https://ClinicalTrials.gov/show/NCT04440930"
395,"NCT04424641","A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Subjects With Malignant Solid Tumors","Not yet recruiting","No Results Available","Dose Escalation Part: Locally Advanced or Metastatic Solid Tumor(s)|Expansion Part: Prostate Cancer|Expansion Part: Esophageal Cancer|Expansion Part: Triple Negative Breast Cancer (TNBC)|Expansion Part: Squamous Cell Carcinoma of Head and Neck (SCCHN)|Expansion Part: Non-small Cell Lung Cancer (NSCLC)|Expansion Part: Bladder Cancer|Expansion Part: Uterine Cancer","Biological: GEN1044 is an IgG1 bispecific antibody targeting CD3 and 5T4.","June 11, 2020","Tennesse Oncology, PLLC - Nashville, Nashville, Tennessee, United States|Rigshospitalet (Copenhagen University Hospital), Copenhagen, Denmark|Chaim Sheba Medical Center, Ramat Gan, Israel|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Fundacion Jimenez Diaz, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04424641"
396,"NCT04438564","Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients","Recruiting","No Results Available","Breast Cancer|Colorectal Cancer|Cancer of Ovary|Cancer of Endometrium","Other: Cases for patients diagnosed with breast cancer, colonrectal cancer, ovarian cancer and endometrial cancer","June 19, 2020","China Medical University Hospital, Taichung, Taiwan","https://ClinicalTrials.gov/show/NCT04438564"
397,"NCT04345081","Examining the Cosmetic Results, Quality of Life and Patient Satisfaction Achieved With Skin Reducing Nipple Sparing Mastectomy and Implant Based Breast Reconstruction, and Comparing it to Classic Skin- Sparing Mastectomy and Implant- Based Breast Reconstructive Surgeries","Recruiting","No Results Available","Breast Cancer|Mastectomy; Lymphedema|Quality of Life|Patient Satisfaction","Procedure: Skin Reducing Nipple Sparing Mastectomy and Implant Based Breast Reconstruction|Procedure: Skin- Sparing Mastectomy and Implant- Based Breast Reconstructive Surgery","April 14, 2020","National Institute of Oncology, Budapest, Hungary","https://ClinicalTrials.gov/show/NCT04345081"
398,"NCT04255225","Making Activity Time for Cognitive Health","Completed","No Results Available","Breast Cancer|Cancer-related Problem/Condition|Cognitive Impairment|Physical Activity","Behavioral: Walking for 10 minutes|Behavioral: Walking for 20 minutes|Behavioral: Walking for 30 minutes","February 5, 2020",,"https://ClinicalTrials.gov/show/NCT04255225"
399,"NCT04419077","Interest of Virtual Reality to Prevent Cancer Patient Anxiety Before Chemotherapy or an Invasive Act","Not yet recruiting","No Results Available","Anxiety|Chemotherapy Effect|Breast Cancer|Head Cancer Neck","Behavioral: Virtual reality exposure","June 5, 2020","Service d'oncologie médicale, Institut de Cancérologie des Hospices Civils de Lyon, Hôpital Lyon sud, Pierre-Bénite, France","https://ClinicalTrials.gov/show/NCT04419077"
400,"NCT04215861","Clinical Study on Raman Spectra of Blood, Saliva and Urine in Patients With Cancer Treated by Modern Therapy","Recruiting","No Results Available","Lung Cancer|Liver Cancer|Stomach Cancer|Breast Cancer",,"January 2, 2020","The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China","https://ClinicalTrials.gov/show/NCT04215861"
401,"NCT04267315","Trigger Point Injections for Post-Mastectomy Pain Syndrome","Not yet recruiting","No Results Available","Post-mastectomy Pain Syndrome|Myofascial Pain Syndrome|Trigger Point Pain, Myofascial|Breast Cancer","Procedure: Trigger point injection|Procedure: Subcutaneous saline injection|Other: Comprehensive Rehabilitation program","February 12, 2020",,"https://ClinicalTrials.gov/show/NCT04267315"
402,"NCT04282044","Study of CRX100 in Patients With Advanced Solid Tumors","Not yet recruiting","No Results Available","Solid Tumor, Adult|Triple Negative Breast Cancer|Colorectal Cancer|Hepatocellular Carcinoma|Osteosarcoma|Epithelial Ovarian Cancer|Gastric Cancer","Biological: CRX100 suspension for infusion","February 24, 2020",,"https://ClinicalTrials.gov/show/NCT04282044"
403,"NCT04344795","Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors","Recruiting","No Results Available","Solid Tumor|Microsatellite-stable Colorectal Cancer (MSS CRC)|Adenocarcinoma of the Lung|Squamous Cell Carcinoma of Head and Neck|Bladder Cancer|Triple Negative Breast Cancer|Gastric Cancer","Drug: TPST-1495|Drug: Pembrolizumab","April 14, 2020","START Midwest, Grand Rapids, Michigan, United States|Carolina BioOncology Institute, Huntersville, North Carolina, United States|South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT04344795"
404,"NCT04401189","The Role of Circadian Rhythms in Cancer-Related Symptoms","Not yet recruiting","No Results Available","Breast Cancer|Fatigue|Cognitive Impairment|Sleep|Depression|Quality of Life|Stress, Psychological|Inflammation|Circadian Rhythm Disorders|Cancer-Related Syndrome",,"May 26, 2020","Aarhus University Hospital, Aarhus, Denmark","https://ClinicalTrials.gov/show/NCT04401189"
405,"NCT04257045","Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives","Recruiting","No Results Available","Breast Carcinoma|Deleterious CDH1 Gene Mutation|Deleterious DICER1 Gene Mutation|Deleterious SMARCA4 Gene Mutation|Deleterious STK11 Gene Mutation|Endometrial Carcinoma|Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Carcinoma","Other: Interview|Other: Questionnaire Administration|Other: Survey Administration","February 5, 2020","University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|M D Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04257045"
406,"NCT04410224","Study of ASN004 in Patients With Advanced Solid Tumors","Not yet recruiting","No Results Available","Breast Cancer|Breast Neoplasms|Breast Adenocarcinoma|Breast Cancer Recurrent|Breast Cancer Metastatic|Breast Cancer Invasive|Non-small Cell Lung Cancer|Non-small Cell Carcinoma|Non-small Cell Lung Cancer Recurrent|Non-Small Cell Squamous Lung Carcinoma|Non-Small Cell Adenocarcinoma|Non-small Cell Lung Cancer Metastatic|Colorectal Cancer|Colorectal Neoplasms|Colorectal Carcinoma|Colorectal Adenocarcinoma|Colorectal Cancer Metastatic|Colorectal (Colon or Rectal) Cancer|Colon Cancer|Colon Neoplasm|Ovarian Cancer|Ovarian Neoplasm|Ovarian Cancer Recurrent|Carcinoma, Ovarian Epithelial|Carcinoma Ovary|Carcinoma Colon|Carcinoma Breast|Carcinoma, Non-Small-Cell Lung","Drug: ASN004","June 1, 2020",,"https://ClinicalTrials.gov/show/NCT04410224"
407,"NCT04234113","Study of SO-C101 and SO-C101in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors","Recruiting","No Results Available","Thyroid|Renal Cell Carcinoma|Non Small Cell Lung Cancer|Small-cell Lung Cancer|Bladder Cancer|Melanoma|Merkel Cell Carcinoma|Skin Squamous Cell Carcinoma|Microsatellite Instability High|Triple Negative Breast Cancer|Mesothelioma|Thymic Cancer|Cervical Cancer|Biliary Tract Cancer|Hepatocellular Carcinoma|Ovarian Cancer|Gastric Cancer|Head and Neck Squamous Cell Carcinoma|Anal Cancer","Drug: SO-C101|Drug: pembrolizumab","January 21, 2020","Yale Cancer Center, New Haven, Connecticut, United States|MD Anderson Cancer Center, Houston, Texas, United States|Institut Gustave Roussy, Paris, France|Vall d'Hebron Institute of Oncology, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT04234113"
408,"NCT04260620","Delphinus SoftVue™ ROC Reader Study (DMT SV RRS3)","Enrolling by invitation","No Results Available","Breast Cancer Detection|Dense Breast Parenchyma|Benign Breast Findings|Normal Breast Screening|Abnormal Breast Screening","Device: Reading of Automated Breast Ultrasound in conjunction with Screening Mammography","February 7, 2020","Delphinus Medical Technologies, Inc., Novi, Michigan, United States","https://ClinicalTrials.gov/show/NCT04260620"
409,"NCT04319757","ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors","Recruiting","No Results Available","Locally Advanced Solid Tumor|Metastatic Cancer|Solid Tumor|HER2-positive Gastric Cancer|HER2-positive Metastatic Breast Cancer","Drug: ACE1702|Drug: Cyclophosphamide|Drug: Fludarabine","March 24, 2020","MD Anderson Cancer Center, Houston, Texas, United States|Peninsula Cancer Institute, Newport News, Virginia, United States","https://ClinicalTrials.gov/show/NCT04319757"
410,"NCT04260802","A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers","Not yet recruiting","No Results Available","Cancer|Neoplasms|Metastatic Cancer|Triple Negative Breast Cancer|Gastric Cancer|Cervical Cancer|Ovarian Cancer|Hepatocellular Carcinoma|Squamous Cell Carcinoma of Head and Neck|Urothelial Carcinoma|Urothelial Neoplasm|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Locally Advanced Solid Tumor|Locally Advanced Malignant Neoplasm|Squamous Cell Carcinoma|Sarcoma|Merkel Cell Carcinoma|Bladder Cancer","Drug: OC-001|Drug: OC-001 in Combination","February 7, 2020","Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Jewish General Hospital - Clinical Research Unit, Montreal, Quebec, Canada|Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT04260802"
411,"NCT04259762","Enhancing Cancer Prevention and Control Pathways—Native Health Initiative","Not yet recruiting","No Results Available","Cancer, Breast|Cancer, Colon|Cancer, Cervix","Behavioral: Breast, Colorectal, and Cervical Cancer Screening Interventions","February 6, 2020",,"https://ClinicalTrials.gov/show/NCT04259762"
412,"NCT04429542","Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors","Recruiting","No Results Available","TNBC - Triple-Negative Breast Cancer|Head and Neck Squamous Cell Carcinoma|Squamous Cell Carcinoma of Anal Canal|Uveal Melanoma|Glioblastoma|Colorectal Cancer|Chordoma|Squamous Cell Carcinoma of the Lung|KRAS G12D|KRAS G13D|EGFR Amplification|Epithelial Ovarian Cancer|Hepatocellular Carcinoma|Anaplastic Thyroid Cancer|Pancreas Cancer","Drug: BCA101|Drug: Pembrolizumab","June 12, 2020","Dana Farber/Partners Cancer Care Inc, Boston, Massachusetts, United States|Memorial Sloan Kettering, New York, New York, United States|Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04429542"
413,"NCT04244552","First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies","Recruiting","No Results Available","Breast Cancer|Colorectal Cancer|Ovarian Cancer|Non Small Cell Lung Cancer|Acral Lentiginous Melanoma","Biological: ATRC-101","January 28, 2020","Carolina BioOncology Institute, Huntersville, North Carolina, United States","https://ClinicalTrials.gov/show/NCT04244552"
414,"NCT04398446","Effect of Hemp-CBD on Patients With CIPN","Recruiting","No Results Available","Chemotherapy-induced Peripheral Neuropathy|Colorectal Cancer Stage II|Colorectal Cancer Stage III|Breast Cancer|Ovarian Cancer","Drug: Hemp-based CBD|Other: Placebo oral tablet","May 21, 2020","Lankenau Medical Center, Wynnewood, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04398446"
415,"NCT04307355","Continuous Diffusion of Oxygen Treatment for Incision Wounds for Cancer Patients","Not yet recruiting","No Results Available","Surgical Wound|Breast Cancer|Mastectomy|Tissue Necrosis|Incision Wound","Device: Transcu O2®","March 13, 2020",,"https://ClinicalTrials.gov/show/NCT04307355"
416,"NCT04435964","Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment","Not yet recruiting","No Results Available","Melanoma|Lung Cancer|Head and Neck Cancer|Urogenital Neoplasms|Breast Cancer","Drug: Immunotherapy","June 17, 2020","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy","https://ClinicalTrials.gov/show/NCT04435964"
417,"NCT04317690","Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey","Enrolling by invitation","No Results Available","High Cholesterol|High Blood Pressure|Colorectal Cancer|Breast Cancer|Prostate Cancer",,"March 23, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04317690"
418,"NCT04222413","Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors","Not yet recruiting","No Results Available","Advanced Solid Tumors|Metastatic Pancreatic Cancer|Pediatric Solid Tumor|Advanced Breast Cancer|Malignant Peripheral Nerve Sheath Tumor","Drug: Metarrestin","January 10, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT04222413"
419,"NCT04331535","The Genomic Medicine at VA Study","Recruiting","No Results Available","Coronary Artery Disease|Atrial Fibrillation|Type 2 Diabetes|Colorectal Cancer|Breast Cancer|Prostate Cancer","Diagnostic Test: Polygenic risk score (PRS)","April 2, 2020","VA Boston Healthcare System, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04331535"
420,"NCT04326660","SCOPE-Chinese Women Study","Not yet recruiting","No Results Available","Cancer, Breast|Obesity, Abdominal","Other: SCOPE-Chinese Women","March 30, 2020","University of California, San Francisco, San Francisco, California, United States|Central South University, Yuelu, Changsha, Hunan, China","https://ClinicalTrials.gov/show/NCT04326660"
421,"NCT04278144","A First-in-human Study Using BDC-1001 in Advanced and HER2-Expressing Solid Tumors","Recruiting","No Results Available","Neoplasm, Metastatic|Neoplasm, Breast|Neoplasm, Gastric","Drug: BDC-1001|Drug: Pembrolizumab","February 20, 2020","Bolt Investigative Site, Grand Rapids, Michigan, United States|Bolt Investigative Site, Pittsburgh, Pennsylvania, United States|Bolt Investigative Site, Houston, Texas, United States|Bolt Investigative Site, San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT04278144"
422,"NCT04348643","Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer","Recruiting","No Results Available","Solid Tumor|Lung Cancer|Colorectal Cancer|Liver Cancer|Pancreatic Cancer|Gastric Cancer|Breast Cancer","Biological: CEA CAR-T cells","April 16, 2020","Chongqing University Cancer Hospital, Chongqing, Chongqing, China","https://ClinicalTrials.gov/show/NCT04348643"
423,"NCT04352530","Culturally Appropriate Nutrition Communication for Mexican American Women","Active, not recruiting","No Results Available","Lifestyle Risk Reduction|Nutrition Poor|Chronic Disease|Obesity|Cancer, Breast","Other: Health Communication","April 20, 2020","University of California Merced SONA System (Online Platform), Merced, California, United States","https://ClinicalTrials.gov/show/NCT04352530"
424,"NCT04348916","Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors","Recruiting","No Results Available","Cancer|Melanoma|Solid Tumor|Squamous Cell Carcinoma of Head and Neck|Breast Cancer|Advanced Solid Tumor","Biological: ONCR-177|Biological: pembrolizumab","April 16, 2020","City of Hope, Duarte, California, United States|Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Sarah Cannon Research Institute - Tennessee Oncology, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT04348916"
425,"NCT04354246","COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies","Recruiting","No Results Available","Advanced Cancer|Ovarian Cancer|Lung Cancer|Colon Cancer|Plasma Cell Neoplasm|Breast Cancer","Drug: COM902","April 21, 2020","START Midwest., Grand Rapids, Michigan, United States|The START Center for Cancer Care., San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT04354246"
426,"NCT04351139","Impact of the COVID-19 Pandemic in Gynecological Oncology","Recruiting","No Results Available","Gynecologic Cancer|Breast Neoplasm Female|Uterine Neoplasms|Ovarian Neoplasms|Uterine Cervical Neoplasms|Vulvar Neoplasms|Vaginal Neoplasms","Other: modification of the planned therapeutic management","April 17, 2020","Service de Gynécologie, HFME, Hospices Civils de Lyon, Bron, France|Service de Gynécologie, Croix-Rousse, Hospices Civils de Lyon, Lyon, France|Service Gynécologie, CHLS, Hospices Civils de Lyon, Pierre-Bénite, France","https://ClinicalTrials.gov/show/NCT04351139"
427,"NCT04285996","IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer Types","Active, not recruiting","No Results Available","Cancer","Procedure: PET Scan","February 26, 2020","Barts Health NHS Trust, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04285996"
428,"NCT04402606","Study on Skin Toxicities Induced by Cancer Treatments","Not yet recruiting","No Results Available","Solid Tumor, Adult|Breast Cancer|Lung Cancer|Digestive System Cancer|Ear Cancer|Nose Cancer|Throat Cancer","Other: Evaluation on skin toxicities","May 27, 2020","Institut Curie, Paris, France","https://ClinicalTrials.gov/show/NCT04402606"
429,"NCT04273061","Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity","Recruiting","No Results Available","Breast Cancer|Lung Cancer|Gastrointestinal Cancer|Genitourinary Cancer|Gynecologic Cancer|Sarcoma|Unknown Primary Tumors|Head and Neck Cancer|Skin Cancer","Drug: Atezolizumab","February 17, 2020","BC Cancer, Vancouver, British Columbia, Canada","https://ClinicalTrials.gov/show/NCT04273061"
430,"NCT04237090","Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel","Recruiting","No Results Available","Breast Cancer|Lung Cancer|Ovarian Cancer|Oesophageal Cancer|Head Cancer Neck|Cervical Cancer|Endometrial Cancer","Drug: Diphenhydramine|Drug: Cetirizine|Drug: Lactose pill|Drug: Sodium chloride 0.9%","January 22, 2020","CIUSSS de l'Est-de-l'île-de-Montréal, Montréal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT04237090"
431,"NCT04440943","A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies","Not yet recruiting","No Results Available","Non-small Cell Lung Cancer|Breast Cancer|Gastric Cancer|Renal Cell Carcinoma|Ovarian Cancer|Primary Peritoneal Carcinoma|Fallopian Tube Cancer|Cholangiocarcinoma|Bladder Urothelial Carcinoma|MSI-H Colorectal Cancer|Esophageal Cancer|Hepatic Cancer|Head and Neck Cancer|Other Solid Tumors","Drug: CDX-527","June 22, 2020",,"https://ClinicalTrials.gov/show/NCT04440943"
432,"NCT04334239","Effectiveness of Care in Certified Cancer Centres in Germany","Enrolling by invitation","No Results Available","Colorectal Cancer|Breast Cancer|Ovarian Cancer|Cervix Cancer|Endometrial Cancer|Bronchial Cancer|Prostate Cancer|Head and Neck Tumor|CNS Tumor|Pancreatic Cancer","Other: Oncological certification","April 6, 2020","Technische Universität Dresden, Dresden, Sachsen, Germany","https://ClinicalTrials.gov/show/NCT04334239"
433,"NCT04389632","A Study of SGN-B6A in Advanced Solid Tumors","Recruiting","No Results Available","Non-small Cell Lung Cancer|Head and Neck Squamous Cell Cancer|Breast Cancer|Esophageal Cancer|Ovarian Cancer|Cutaneous Squamous Cell Cancer|Exocrine Pancreatic Adenocarcinoma|Bladder Cancer|Cervical Cancer|Gastric Cancer","Drug: SGN-B6A","May 15, 2020","Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT04389632"
434,"NCT04235556","Integrated Care Pathway in Oncology (PASSION)","Recruiting","No Results Available","Colon Cancer|Gastric Cancer|Pancreatic Cancer|Thoracic Neoplasms|Breast Cancer|Ovarian Cancer|Bladder Cancer|Prostate Cancer","Behavioral: Care pathway unit","January 22, 2020","AP-HP Hôpital européen Georges-Pompidou, Paris, France","https://ClinicalTrials.gov/show/NCT04235556"
435,"NCT04430842","Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S","Not yet recruiting","No Results Available","Astrocytoma|Brain Cancer|Brain Metastases|Bladder Cancer|Breast Cancer|Cervical Cancer|Cholangiocarcinoma|Colorectal Cancer|Esophagus Cancer|Gastric Cancer|Head and Neck Cancer|Kidney Cancer|Liver Cancer|Lung Cancer|Melanoma|Ovarian Cancer|Pancreatic Cancer|Pleural Mesothelioma|Prostate Cancer|Sarcoma|Tongue Cancer|Thymic Carcinoma|Urinary Tract Cancer","Drug: QBS10072S","June 12, 2020","St George Private Hospital, Kogarah, New South Wales, Australia|Sydney Southwest Private Hospital, Liverpool, New South Wales, Australia","https://ClinicalTrials.gov/show/NCT04430842"
436,"NCT04354064","Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors","Recruiting","No Results Available","Healthy Volunteer|Prostate Cancer|Head and Neck Cancer|Esophageal Cancer|Genitourinary Cancer|Sarcoma|Breast Cancer|Colon Cancer|Gastrointestinal Cancer|Solid Tumor Cancer|Lung Cancer|Skin Cancer|Melanoma",,"April 21, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States","https://ClinicalTrials.gov/show/NCT04354064"
437,"NCT04267575","Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites","Recruiting","No Results Available","Recurrent Malignant Solid Neoplasm|Stage IV Breast Cancer|Stage IV Prostate Cancer|Stage IV Pancreatic Cancer|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Cancer|Stage IV Fallopian Tube Cancer|Stage IV Colon Cancer|Stage IV Colorectal Cancer|Stage IV Liver Cancer|Stage IV Renal Cell Cancer|Stage IV Rectal Cancer|Stage IV Lung Cancer|Stage IV Small Intestinal Cancer|Stage IV Gastric Cancer|Stage IV Bladder Cancer","Device: Canady Helios Cold Plasma Scalpel","February 13, 2020","Canady Surgical Group PC, Washington, District of Columbia, United States","https://ClinicalTrials.gov/show/NCT04267575"
438,"NCT04436120","Treatment Resistance Following Anti-cancer Therapies","Recruiting","No Results Available","Disease Progression","Procedure: De novo tumor tissue biopsy|Procedure: Research blood draws","June 17, 2020","Southern Cancer Center, P.C., Daphne, Alabama, United States|Southern Cancer Center, PC, Mobile, Alabama, United States|Southern Cancer Center, PC, Mobile, Alabama, United States|Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, United States|Arizona Oncology Associates, PC-HOPE, Tucson, Arizona, United States|Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|PMK Medical Group Inc., dba Ventura County Hematology Oncology Specialists, Camarillo, California, United States|The Oncology Institute of Hope Innovation, Glendale, California, United States|The Oncology Institute of Hope Innovation, Long Beach, California, United States|UCI Medical Center-Chao Family Comprehensive Cancer Center, Orange, California, United States|PMK Medical Group Inc., dba Ventura County Hematology Oncology Specialists, Oxnard, California, United States|The Oncology Institute of Hope Innovation, Santa Ana, California, United States|Sansum Clinic, Santa Barbara, California, United States|PMK Medical Group Inc., dba Ventura County Hematology Oncology Specialists, Ventura, California, United States|The Oncology Institute of Hope and Innovation, Whittier, California, United States|ICRI-Administrative and Supplies Only, Whittier, California, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Boulder, Colorado, United States|Rocky Mountain Cancer Centers, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Englewood, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers, Littleton, Colorado, United States|Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States|Rocky Mountain Cancer Centers, Longmont, Colorado, United States|Rocky Mountain Cancer Centers, Parker, Colorado, United States|Rocky Mountain Cancer Centers, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers, Thornton, Colorado, United States|Woodlands Medical Specialists, Pensacola, Florida, United States|Oncology Hematology West, P.C. dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|Oncology Hematology West, P.C. dba Nebraska Cancer Specialists, Papillion, Nebraska, United States|Charleston Oncology, P.A., Charleston, South Carolina, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Instituto Medico Especializado Alexander Fleming, Caba, Buenos Aires, Argentina|Clínica Viedma S.A., Viedma, RIO Negro, Argentina|Instituto de Oncologia de Rosario, Rosario, Santa FE, Argentina|Sanatorio de la Mujer, Rosario, Santa FÉ, Argentina|Centro para la Atencion Integral del Paciente Oncologico (CAIPO), San Migeuel De Tucuman, Tucuman, Argentina|Centro Medico San Roque SRL, San Miguel de Tucuman, Tucuman, Argentina|Hospital Britanico de Buenos Aires, Caba, Argentina|Centro de Educacion Medica e Investigaciones Clinicas""Norberto Quirno"" CEMIC, Ciudad Autónoma de Bs As, Argentina|Universitaetsklinikum Krems, Krems, Austria|Imelda Ziekenhuis, Bonheiden, Belgium|Grand Hôpital de Charleroi - Site Notre Dame, Charleroi, Belgium|AZ Maria Middelares, Gent, Belgium|UZ Gent, Gent, Belgium|Hôpital de Jolimont, Haine-Saint-Paul, Belgium|Jessa Ziekenhuis, Hasselt, Belgium|CHU UCL Namur/Site Sainte Elisabeth, Namur, Belgium|Clinique Saint-Pierre Ottignies, Ottignies, Belgium|GZA Ziekenhuizen campus Sint-Augustinus, Wilrijk, Belgium|Centre Jean Perrin, Clermont Ferrand, France|Hôpitaux Civils de Colmar, Centre Hospitalier Louis Pasteur, Colmar, France|Centre Hospitalier Intercommunal de Créteil, Créteil, France|CHU Henri Mondor, Créteil, France|Centre Georges- François Leclerc, Dijon, France|Clinique de la Sauvegarde, Lyon Cedex 09, France|Polyclinique de Gentilly, Nancy, France|Hôpital La Croix du Sud, Quint Fonsegrives, France|Institut Jean Godinot, Reims Cedex, France|Centre Hospitalier Privé Saint-Grégoire, Saint Grégoire, France|Hopital Bégin, Saint-Mande, France|Urologische Praxis am Wasserturm, Wuerselen, Germany|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coruna, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Royal Cornwall Hospital, Cornwall, United Kingdom|Musgrove Park Hospital, Taunton, United Kingdom","https://ClinicalTrials.gov/show/NCT04436120"
439,"NCT04427449","4SCAR-CD44v6 T Cell Therapy Targeting Cancer","Recruiting","No Results Available","Cancers Which Are CD44v6 Positive","Biological: CD44v6-specific CAR gene-engineered T cells","June 11, 2020","Shenzhen Children's Hospital, Shenzhen, Guangdong, China|Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China|Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong, China|The Seventh Affilliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, China","https://ClinicalTrials.gov/show/NCT04427449"
440,"NCT04444427","Evaluation of GLR2007 for Advanced Solid Tumors","Not yet recruiting","No Results Available","Non-small Cell Lung Cancer|Glioblastoma Multiforme","Drug: GLR2007","June 23, 2020","USA03, Port Saint Lucie, Florida, United States|USA02, Lafayette, Indiana, United States|USA01, Philadelphia, Pennsylvania, United States|USA04, Dallas, Texas, United States","https://ClinicalTrials.gov/show/NCT04444427"
441,"NCT04298398","Impact of Group Psychological Interventions on Extracellular Vesicles in People Who Had Cancer","Not yet recruiting","No Results Available","Cancer","Behavioral: Mindfulness Based-Cognitive Therapy (MBCT)|Behavioral: Emotion Focused Therapy Group for Cancer Recovery (EFT-CR)|Other: Treatment as usual (no intervention)","March 6, 2020",,"https://ClinicalTrials.gov/show/NCT04298398"
442,"NCT04258813","Onco-primary Care Networking to Support TEAM-based Care","Not yet recruiting","No Results Available","Blood Pressure|Hypertension|Cancer|Cancer, Breast|Cancer of Prostate|Cancer Colorectal|Cancer, Endometrial|Cancer of Head and Neck|Non Small Cell Lung Cancer|CVD - Cardiovascular Disease|Diabetes Mellitus|Hypercholesterolemia|Diabetes","Behavioral: iGuide Intervention (Self-guided)|Behavioral: iGuide 2 Intervention (Tailored/Targeted)|Behavioral: Control","February 6, 2020","Duke University Medical Center, Durham, North Carolina, United States","https://ClinicalTrials.gov/show/NCT04258813"
443,"NCT04225117","A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","Recruiting","No Results Available","Locally Advanced or Metastatic Malignant Solid Tumors","Drug: enfortumab vedotin","January 13, 2020","Piedmont Hospital, Atlanta, Georgia, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States|Site JP81004, Nagoya, Aichi, Japan|Site JP81001, Kashiwa, Chiba, Japan|Site JP81003, Chuo, Tokyo, Japan|Site JP81002, Koto, Tokyo, Japan","https://ClinicalTrials.gov/show/NCT04225117"
444,"NCT04293094","Study of AMG 650 in Adult Participants With Advanced Solid Tumors","Recruiting","No Results Available","Advanced Solid Tumors","Drug: AMG 650","March 3, 2020","Research Site, Santa Monica, California, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Woodville South, South Australia, Australia","https://ClinicalTrials.gov/show/NCT04293094"
445,"NCT04306900","TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers","Recruiting","No Results Available","Solid Tumor, Adult","Combination Product: TTX-030, budigalimab and mFOLFOX6|Combination Product: TTX-030, budigalimab and docetaxel|Combination Product: TTX-030 and mFOLFOX6|Combination Product: TTX-030 and budigalimab","March 13, 2020","Ocala Oncology Center PL, Ocala, Florida, United States|Nebraska Cancer Center Oncology Hematology West P.C., Omaha, Nebraska, United States|West Cancer Center and Research Institute, Germantown, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|NEXT Oncology, San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT04306900"
446,"NCT04373564","Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years","Not yet recruiting","No Results Available","Motor Function|Cognitive Function|Contrast Media","Procedure: Motor Tests|Procedure: Cognitive Tests|Procedure: Unenhanced-MRI of the brain|Procedure: Gadolinium Measurements|Drug: Gadoxetate disodium|Drug: Gadobenate dimeglumine|Drug: Gadodiamide|Drug: Gadoterate meglumine|Drug: Gadobutrol|Drug: Gadoteridol","May 4, 2020",,"https://ClinicalTrials.gov/show/NCT04373564"
447,"NCT04300556","A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","Not yet recruiting","No Results Available","Solid Tumor","Drug: MORAb-202","March 9, 2020",,"https://ClinicalTrials.gov/show/NCT04300556"
448,"NCT04434560","Neoadjuvant Immunotherapy in Brain Metastases","Not yet recruiting","No Results Available","Brain Metastases, Adult","Drug: Nivolumab|Drug: Ipilimumab","June 17, 2020","Duke University Medical Center, Durham, North Carolina, United States","https://ClinicalTrials.gov/show/NCT04434560"
449,"NCT04252300","Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants","Recruiting","No Results Available","Drug Interactions","Drug: Rosuvastatin|Drug: Rosuvastatin + BAY1817080","February 5, 2020","Covance Clinical Research Unit, Inc., Daytona Beach, Florida, United States","https://ClinicalTrials.gov/show/NCT04252300"
